# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Summary</strong></td>
<td>3</td>
</tr>
<tr>
<td><strong>Basics</strong></td>
<td>4</td>
</tr>
<tr>
<td>Definition</td>
<td>4</td>
</tr>
<tr>
<td>Epidemiology</td>
<td>4</td>
</tr>
<tr>
<td>Aetiology</td>
<td>5</td>
</tr>
<tr>
<td>Pathophysiology</td>
<td>5</td>
</tr>
<tr>
<td>Classification</td>
<td>6</td>
</tr>
<tr>
<td><strong>Prevention</strong></td>
<td>8</td>
</tr>
<tr>
<td>Primary prevention</td>
<td>8</td>
</tr>
<tr>
<td>Screening</td>
<td>8</td>
</tr>
<tr>
<td>Secondary prevention</td>
<td>9</td>
</tr>
<tr>
<td><strong>Diagnosis</strong></td>
<td>11</td>
</tr>
<tr>
<td>Case history</td>
<td>11</td>
</tr>
<tr>
<td>Step-by-step diagnostic approach</td>
<td>11</td>
</tr>
<tr>
<td>Risk factors</td>
<td>19</td>
</tr>
<tr>
<td>History &amp; examination factors</td>
<td>20</td>
</tr>
<tr>
<td>Diagnostic tests</td>
<td>25</td>
</tr>
<tr>
<td>Differential diagnosis</td>
<td>30</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>32</td>
</tr>
<tr>
<td>Step-by-step treatment approach</td>
<td>32</td>
</tr>
<tr>
<td>Treatment details overview</td>
<td>34</td>
</tr>
<tr>
<td>Treatment options</td>
<td>36</td>
</tr>
<tr>
<td>Emerging</td>
<td>46</td>
</tr>
<tr>
<td><strong>Follow up</strong></td>
<td>47</td>
</tr>
<tr>
<td>Recommendations</td>
<td>47</td>
</tr>
<tr>
<td>Complications</td>
<td>48</td>
</tr>
<tr>
<td>Prognosis</td>
<td>49</td>
</tr>
<tr>
<td><strong>Guidelines</strong></td>
<td>50</td>
</tr>
<tr>
<td>Diagnostic guidelines</td>
<td>50</td>
</tr>
<tr>
<td>Treatment guidelines</td>
<td>52</td>
</tr>
<tr>
<td><strong>Online resources</strong></td>
<td>53</td>
</tr>
<tr>
<td><strong>References</strong></td>
<td>54</td>
</tr>
<tr>
<td><strong>Images</strong></td>
<td>63</td>
</tr>
<tr>
<td><strong>Disclaimer</strong></td>
<td>77</td>
</tr>
</tbody>
</table>
Syphilis is a common sexually transmitted infection. An estimated 6 million new infections occurred worldwide in 2016.

Caused by the spirochaetal bacterium Treponema pallidum, subspecies pallidum.

Clinical presentation is often asymptomatic, but can manifest in a number of ways.

A painless ulcer (chancre) in the anogenital region is a hallmark of primary infection.

Diagnosis is usually straightforward after clinical examination and serological tests. Treatment is with penicillin.

Untreated syphilis facilitates HIV transmission and causes considerable morbidity, such as cardiovascular and neurological disease, as well as a congenital syndrome in the newborn.

Syphilis in pregnancy is a major cause of miscarriage, stillbirth, and perinatal morbidity and mortality in some parts of the world.
Definition

Syphilis is a sexually transmitted infection caused by the spirochaetal bacterium *Treponema pallidum*, subspecies *pallidum*. It is found only in human hosts. Acquired infection is transmitted through direct person-to-person sexual contact with an individual with early (primary or secondary) syphilis. Most sexual transmission of syphilis probably occurs from direct contact with syphilitic lesions on the genitals or mucous membranes. Transmission from mother to fetus during pregnancy causes congenital infection. Syphilis has often been described as the great imitator because many of the symptoms and signs are difficult to distinguish from other diseases.[1]

Epidemiology

Syphilis is a common STI. There were an estimated 6 million new cases of syphilis worldwide in 2016.[8]

Syphilis in the US:

In 2017, the incidence rate of primary and secondary syphilis was 9.5 cases in 100,000 population (30,644 new cases).[9] This represents a 10.5% increase from 2016 (8.6 cases in 100,000 population), and a 72.2% increase from 2013 (5.5 cases in 100,000 population). Over half (57.9%) of all reported cases of primary and secondary syphilis occurred in men who have sex with men (MSM). The incidence rate of primary and secondary syphilis was 16.9 cases in 100,000 men in 2017, and 2.3 cases in 100,000 women.[9] In men, the incidence rate was highest in the age group 25-29 years, followed by age groups 20-24 years and 30-34 years (incidence was similar in these two age groups). In women, the highest rate was in the age group 20-24 years, followed by age group 25-29 years.

In 2017, the incidence rate of primary and secondary syphilis was highest in black people (24.2 cases in 100,000 population).[9] The incidence rate in black people was 4.5 times higher than in white people (5.4 cases in 100,000 population). From 2013-2017, rates have increased among all race/ethnicity groups. Between 2016-2017, the greatest increase was observed among American Indians/Alaska Natives (38.8%), and those identified as multi-racial (31.7%), followed by Asians (15.7%), white people (10.2%), Native Hawaiians/other Pacific Islanders (9.4%), Hispanics (9.3%), and black people (5.7%).[9]

The incidence of congenital syphilis in 2017 was 23.3 cases in 100,000 live births (628 cases); a 43.8% increase from 2016 (16.2 cases in 100,000 live births) and a 153.3% increase from 2013 (9.2 cases in 100,000 live births).[9]

Syphilis in other countries:

Syphilis has been increasing in Europe since 2011, particularly among MSM.[10] In 2016, there were 29,365 new cases reported across the 28 countries in the European Union (EU) (6.1 cases in 100,000 population). The highest rates were in the UK (9.9 cases in 100,000 population), Malta (9.2), Iceland (9.0), and Germany (8.7). The lowest rates (<2 cases in 100,000 population) were in Croatia, Cyprus, Estonia, Portugal, and Slovenia. The incidence rate was 8 times higher in men (10.8 cases in 100,000 population) than in women (1.3 cases in 100,000 population). The highest age and sex-specific rate was in men aged 25-34 years (25 cases in 100,000 population).[10]

In London, UK, the number of syphilis diagnoses reported in 2017 (3,397) was double the number reported in 2013.[11]
Thirty-seven congenital syphilis cases were reported in 23 EU/European Economic Area Member States in 2016.[12] This represents a crude rate of 1.1 cases in 100,000 live births.

In China, where syphilis was virtually eradicated in the 1950s, both the incidence and prevalence of the disease have more than quadrupled from the 1990s to the 2010s.[13] The increases have been attributed to migration from rural communities to urban environments, limited screening for the presence of the disease, lack of adequate partner notification, and a reluctance by the general population to access STI healthcare services.[14]

Aetiology

Syphilis is caused by *Treponema pallidum* subspecies *pallidum*, a motile spirochaete bacterium. Humans are the only natural host. In-vitro culture is not possible. Entry of *T pallidum* probably occurs via areas of minor abrasion (at genital and mucous membrane sites) that result from trauma during sexual intercourse.[15]

Oro-genital sex is an important route of transmission and, therefore, transmission can occur despite the use of condoms.[16] [17] The risk of acquiring syphilis after sex with someone with primary or secondary syphilis is between 30% and 60%.[18] [19] Other modes of transmission are blood transfusion and transplacental transmission from mother to fetus.

Pathophysiology

Primary syphilis is characterised by ulceration (usually a solitary painless ulcer [chancre]) and local lymphadenopathy. The primary syphilis ulcer contains the *Treponema pallidum* bacterium and is characterised by mononuclear leukocytic infiltration. It heals spontaneously.

Secondary syphilis is caused by haematogenous spread of *T pallidum*. This leads to a widespread vasculitis. The mucocutaneous lesions of secondary syphilis also contain treponemes. The reasons for the resolution of secondary syphilis are unclear, but are likely to be related to a combination of macrophage-driven uptake of opsonised spirochaetes and cell-mediated immunity.

Perivascular infiltrates composed principally of lymphocytes, histiocytes (macrophages), and plasma cells, accompanied by varying degrees of endothelial cell swelling and proliferation, are the histological hallmarks of primary and secondary syphilis lesions. Likewise, *T pallidum* spirochaetes are abundant in early syphilis lesions and are often observed in and around blood vessels and migrating from the dermis into the epidermis.

It is estimated that 15% to 40% of patients with untreated syphilis progress to tertiary syphilis (late symptomatic disease),[6] which includes neurosyphilis, gummatous syphilis, and cardiovascular syphilis. The theory that cell-mediated immunity is important in controlling syphilis infection is supported by the observation that progression to neurosyphilis may be more common in patients co-infected with HIV.

Neurosyphilis may occur at any stage of infection with syphilis, and is characterised by a chronic, insidious inflammation of the meninges. It may occur in up to 10% of patients with untreated syphilis.[20] Neurosyphilis is caused by central nervous system invasion by the *T pallidum* bacterium. Early neurosyphilis syndromes are usually the result of meningovascular involvement; late neurosyphilis may occur due to meningovascular
involvement or direct infection of the brain and spinal cord parenchyma. Parenchymal infection of the spinal cord by *T. pallidum* results in tabes dorsalis. This condition is predominantly due to dorsal column loss. General paresis occurs with parenchymal involvement of the brain with neuronal loss.

Cardiovascular syphilis is characterised by aortic involvement as the *T. pallidum* bacterium causes occlusion of the aortic vasa vasorum resulting in necrosis of the tunica media. Long-term inflammation and scarring weakens the aortic wall, leading to aortic aneurysm formation, as well as aortic incompetence and angina due to narrowing of the coronary ostia.

The hallmark of gummatous syphilis is the appearance of lesions on the skin, liver, bones, and testes. These lesions consist of granulomatous rubbery tissue with a necrotic centre, and they may gradually replace normal tissue. *T. pallidum* is rarely found within these lesions.

### Classification

#### Classification according to transmission

**Acquired syphilis:**

- Transmission through direct person-to-person sexual contact with an individual with early (primary or secondary) syphilis.

**Congenital syphilis:**

- Transmission of syphilis from the mother to the fetus during pregnancy
- May result in miscarriage, stillbirth, or neonatal death[2]
- Sub-divided into:
  - Early (clinical manifestations occur from birth to 2 years of age)
  - Late (clinical manifestations occur at age >2 years).

#### Acquired syphilis, classified according to stage of infection[3]

**Primary syphilis:**

- Initial inoculation of *Treponema pallidum* causes local infection
- A single macule develops, which changes into a papule and then ulcerates, forming a chancre at 9-90 days after exposure (usually 14-21 days after exposure).

**Secondary syphilis:**

- Clinical features develop 4-8 weeks after primary syphilis infection
- Characterised by spirochaetaemia and widespread dissemination of *T. pallidum* to the skin and other tissues.

**Early latent syphilis:**

- Asymptomatic infection diagnosed on the basis of positive serology alone, acquired <1 year previously (according to US Centers for Disease Control and Prevention [CDC] criteria) or <2 years previously (according to World Health Organization [WHO] criteria).[4] [5]
• Relapse to secondary syphilis may occur during the early latent stage.

Late latent syphilis:

• Asymptomatic infection acquired >1 year previously (according to CDC criteria) or >2 years previously (according to WHO criteria)[4] [5]
• The patient is not known to have been seronegative within the past year (according to CDC criteria) or past 2 years (according to WHO criteria).[4] [5]

Tertiary syphilis:

• It is estimated that 15% to 40% of patients with untreated syphilis progress to tertiary syphilis (late symptomatic disease)[6]
• Characterised by chronic end-organ complications, often many years after initial infection
• Includes cardiovascular syphilis, neurosyphilis, and gummatous syphilis.
Primary prevention

Protected sexual intercourse using condoms reduces the transmission of acquired syphilis.[26] However, oro-genital sex is an important route of transmission and can occur despite the use of condoms.[16] [17] There is no significant evidence to suggest that male circumcision reduces the incidence of syphilis.[27] National screening programmes are in place prior to blood donation and as part of antenatal care during pregnancy. Antenatal screening aims to identify and treat asymptomatic women, thus preventing transplacental transmission.[25]

One open-label randomised trial found that post-exposure prophylaxis with a single dose of doxycycline in high-risk men who have sex with men reduced the risk of syphilis compared with no post-exposure prophylaxis at 10-month follow-up (hazard ratio: 0.27; 95% CI: 0.07 to 0.98; p = 0.047).[28]

Screening

Screening for syphilis is important for the following reasons:

- Syphilis infection is often asymptomatic but highly transmissible
- If untreated it causes intra-uterine mortality and considerable morbidity many years after initial infection
- Treatment of syphilis in the early stage of infection is curative and aims to halt disease progression and eliminate further transmission of infection
- Syphilis is an important facilitator of HIV transmission.

Screening is undertaken in:

- Asymptomatic patients who are at risk of the infection[79]
- Pregnant women [USPSTF: syphilis infection in pregnant women - screening]
- Blood donors.[80]

Screening tests

Many laboratories employ a ‘reverse sequence screening algorithm’ whereby a treponemal serology test is used as the initial screening test (usually the treponemal enzyme immunoassay). A treponemal test will identify patients with an infection, but it cannot distinguish between an active infection (i.e., currently untreated or incompletely treated) and a past (treated) infection.[5] [41] [79]

False-negative results may occur in incubating and early primary syphilis. False-positive results may occur with other non-sexually transmitted treponemal infection (e.g., yaws, pinta, bejel).[81]

If the treponemal test is positive, a non-treponemal test, such as the Venereal Disease Research Laboratory (VDRL) or rapid plasma reagin (RPR) test, should be performed to confirm the diagnosis and provide evidence of active disease or re-infection. These tests enable a quantitative value of disease activity (titre) to guide treatment. If the non-treponemal test is subsequently negative, then a different treponemal test should be performed to confirm the results of the initial test.[5]

An alternative approach to screening is the use of a non-treponemal test (VDRL or RPR) as the initial test. Positive tests need to be confirmed by using a treponemal test because false-positive results can occur due to other medical conditions (e.g., pregnancy, autoimmune disorders, other infections).

In resource-poor countries and in non-clinical settings, rapid point-of-care tests (which are recommended by the World Health Organization [WHO]) may have an important role in the control of syphilis and the prevention of adverse outcomes associated with syphilis in pregnancy.[82] [83]
Screening in STI clinic

All patients with an STI should have syphilis screening, as should patients at higher risk of STIs, irrespective of where they are seen. [USPSTF: syphilis infection in nonpregnant adults and adolescents - screening] This includes men who have sex with men (MSM), HIV-infected patients, people with multiple sexual partners, commercial sex workers, and people exchanging sex for drugs.[84] [79] [85] [CDC: sexually transmitted disease surveillance, 2017]

Antenatal screening

Screening of all pregnant women for syphilis infection is recommended by the US Preventive Services Task Force, the Centers for Disease Control and Prevention, the WHO, and the UK National Screening Committee.[4] [5] [86] [79] [87] [USPSTF: syphilis infection in pregnant women - screening] [NSC: the UK NSC recommendation on syphilis screening in pregnancy]

Syphilis serology should be performed on all pregnant women at the first antenatal visit, or as early as possible in pregnancy.[5] [USPSTF: syphilis infection in pregnant women - screening] Serology should be repeated again early in the third trimester and at delivery if serology has been positive, or if there is high maternal risk of syphilis acquisition.[5] The syphilis serological status of the mother should be determined prior to discharge of the infant from the hospital.[5] Antenatal screening is cost-effective, even in areas of low prevalence.[88] Any woman who gives birth to a stillborn infant should be tested for syphilis, and all pregnant women who have syphilis should be tested for HIV.[5]

Antenatal screening detects syphilis infection in asymptomatic pregnant women, enabling treatment to prevent infection in newborns (congenital syphilis), and other associated risks such as miscarriage, stillbirth, or neonatal death.[71] Evidence strongly supports antenatal syphilis screening and early treatment as a measure for preventing congenital syphilis.[89] [90] [87] [91] [92] [93] [USPSTF: syphilis infection in pregnant women - screening]

Clinics that provide on-site rapid syphilis testing, and immediate treatment for positive cases and their partners, may reduce the rate of congenital syphilis in regions where lack of awareness of syphilis infection, and problematic access to antenatal syphilis screening services, are potential issues.[94]

Screening low-risk asymptomatic population

Screening is not recommended if the patient is asymptomatic and not at increased risk of syphilis infection. Given the low incidence of syphilis infection in the general population and the consequent low yield of screening, the potential harms (e.g., of false positives) of screening in a low-incidence population may outweigh the benefits.[79]

Screening for HIV and other STIs

All patients with syphilis should be screened for chlamydia, gonorrhoea, and blood-borne viruses such as hepatitis B and C. All patients with syphilis should be tested for HIV.[5] Syphilis is an important facilitator of HIV transmission. Co-infection is disproportionately high among MSM, particularly those on antiretroviral therapy.[21] [32] A high level of suspicion for the testing and treatment of syphilis in patients with HIV is advisable. In geographical areas in which the prevalence of HIV is high, patients who have primary syphilis should be re-tested for HIV after 3 months even if the first HIV test result is negative.[5] In patients with HIV, serological responses to infection may be atypical, with high, low, or fluctuating titres.

Secondary prevention

All patients with syphilis should be screened for chlamydia, gonorrhoea, and blood-borne viruses, such as hepatitis B and C. All patients with syphilis should be tested for HIV.[5] Syphilis is an important facilitator of HIV transmission. All patients with syphilis should be offered hepatitis B vaccination. Sexual contacts of patients with confirmed syphilis should be screened and offered presumptive treatment if follow-up may be problematic.[5] Antibiotics are the only treatment available for syphilis infection.

Strengthening STI services may have an important role in controlling STIs.[109]
Preventive treatment when there has been sexual contact with an infected person:[5]

- People exposed within 90 days preceding diagnosis of primary, secondary, or early latent syphilis in a sexual partner should be treated presumptively, on the basis that they may be infected even if seronegative. It is estimated that 30% to 60% of sexual partners of people with early syphilis will develop the infection.[18] [19]
- People exposed more than 90 days before diagnosis of primary, secondary, or early latent syphilis in a sexual partner should be treated presumptively if syphilis serology is not available immediately and if follow-up may be problematic.
- Treatment of long-term sexual partners of patients with latent syphilis is dependent on clinical evaluation and serology results.

At-risk time intervals:[5]

- For primary syphilis: exposure 3 months before treatment, plus duration of symptoms.
- For secondary syphilis: 6 months plus duration of symptoms.
- For early latent syphilis: 1 year.

The identification and treatment of syphilis should be used as an opportunity to promote safe-sex awareness, encourage condom use, and highlight health impacts associated with high risk behaviour, such as illicit drug use. Conditional cash incentives to encourage safe sexual practices have demonstrated potential in rural Tanzania.[110]

In cases of sexual assault, UK guidelines recommend that prophylaxis should be considered if the perpetrator is known to have infectious syphilis.[54]

In the US, syphilis is a nationally notifiable disease, per the US Centers for Disease Control and Prevention. Providers should contact their local state health department for details.
Case history

Case history #1

A 27-year-old man notes a painless penile ulcer. He has recently started a new relationship. He is otherwise asymptomatic, as is his partner. On examination, the ulcer is indurated and the inguinal lymph nodes are ruberry and moderately enlarged.

Case history #2

A 30-year-old man presents with difficulty hearing conversations while in a crowded room. Following referral for audiometry, bilateral high-frequency hearing loss is diagnosed. On further questioning he reports a past history of an anal fissure about 10 weeks previously that healed spontaneously. He also describes a mild transient skin rash 2 weeks before his auditory symptoms appeared. He says that he has been feeling unusually tired.

Other presentations

The chancre (syphilitic ulcer) of primary syphilis is usually a solitary, painless, clean ulcer with an indurated base. Less commonly, there may be multiple or painful ulcers. This presentation may represent co-infection with chancroid or genital herpes. Uncommon presentations of secondary syphilis include specific organ involvement, such as hepatitis, iritis, choroidoretinitis, glomerulonephritis, nephrotic syndrome, neurosyphilis involving cranial nerves (particularly the eighth cranial nerve), and meningitis.[7]

Gummata are an extremely rare manifestation of tertiary (late) syphilis. Gummatous syphilis (also known as benign tertiary syphilis) usually affects skin and bone but can also affect visceral organs, causing organomegaly or infiltrative or destructive lesions, as well as perforation or collapse of affected structures.

Step-by-step diagnostic approach

Patients with signs and symptoms of syphilis should undergo diagnostic testing. In patients with asymptomatic infection, diagnosis relies on routine screening.

History

Eliciting a history of sexual activity and risk factors is important when considering the diagnosis of syphilis. People at high risk of infection include those who have had sexual contact with an infected person, men who have sex with men (MSM), people infected with HIV or other STIs, people with multiple sexual partners, commercial sex workers, and people using illicit drugs. Pregnant women with syphilis are at risk of transmitting the infection transplacentally to the fetus.
It is important to establish whether a patient has a history of syphilis (and past treatment), as this can help with the interpretation of diagnostic test results and help confirm the stage of infection.

**Signs and symptoms of primary syphilis**

A solitary painless genital ulcer (chancre) in the anogenital or cervix area strongly suggests a diagnosis of primary syphilis.[29] It may not always be noticed by the patient and examining physician, and it heals spontaneously. There may also be discrete, painless, rubbery regional lymphadenopathy. Mouth ulceration may occur in primary infection. When this occurs, the ulcer is confined to the mouth.

[Fig-2]

[Fig-3]

Atypically, ulceration may be multiple and painful. Co-infection with genital herpes or chancroid may be a cause of painful ulceration. Co-infection with HIV may result in multiple ulcers. Approximately 30% of HIV antibody-negative and 70% of HIV antibody-positive patients with primary syphilis have multiple genital ulcers.

**Signs and symptoms of secondary syphilis**

Patients may develop clinical features of secondary syphilis 4-8 weeks after primary syphilis infection. The presentation of secondary syphilis is diverse. The disseminated treponemal infection has multi-system manifestations. Patients may describe constitutional symptoms including fever, malaise, myalgia, fatigue, or arthralgia. They may also notice generalised lymphadenopathy. These features may be mistaken for an intercurrent viral illness or primary HIV infection. There may be a generalised symmetrical macular, papular, or maculopapular diffuse rash, typically affecting the palms of the hands and plantar aspects of the feet. The rash may also occur on the trunk and scalp. Occasionally the papules may ulcerate. There may be generalised mucosal ulceration, causing 'snail-track' ulcers on the buccal mucosa, and erosions on the genitalia. There may be flesh-coloured wart-like lesions in the genital area, known as condylomata lata. Patchy alopecia may develop.

[Fig-5]

[Fig-6]

[Fig-7]

[Fig-8]

Uncommon presentation includes specific organ involvement. Symptoms of headache, meningismus, hearing loss, seizures, or neuropathy suggest neurological involvement. Neurosyphilis may occur at any stage of infection with syphilis, and may occur in up to 10% of patients with untreated syphilis.[20] Visual changes due to syphilitic iritis, uveitis, and choroidoretinitis may initially present to ophthalmological services.[30] The vasculitis due to secondary syphilis may cause a nephrotic syndrome, glomerulonephritis, or hepatitis.

Up to 25% of people who have untreated secondary syphilis go on to develop relapsing episodes of secondary syphilis. Symptoms include rash and fever. These relapsing episodes rarely occur more than 1 year after acquiring syphilis.
Latent syphilis

Latent syphilis is defined as positive serology in the absence of clinical features of syphilis. Early latent syphilis is defined as asymptomatic infection that is diagnosed on the basis of positive serology alone, acquired <1 year previously (according to the Centers for Disease Control and Prevention [CDC]) or <2 years previously (according to the World Health Organization [WHO]).[4] [5]

Late latent syphilis is defined as asymptomatic infection that is acquired >1 year previously (CDC) or >2 years previously (WHO).[4] [5] The patient is not known to have been seronegative within the past year (CDC) or past 2 years (WHO).[4] [5]

Signs and symptoms of tertiary syphilis

It is estimated that 15% to 40% of patients with untreated syphilis progress to tertiary syphilis (late symptomatic disease).[6] Tertiary syphilis is characterised by chronic, end-organ complications, often many years after initial infection. The diagnosis may be suspected from a past history of features of earlier-stage disease and the presence of risk factors.

Neurosyphilis may involve damage to the dorsal columns of the spinal cord, causing a syndrome known as tabes dorsalis. Features of tabes dorsalis include:

- Ataxia
- Loss of anal and bladder sphincter control
- Argyll-Robertson pupils
- Areflexia
- Dorsal column loss (loss of vibration and proprioception/position sense)
- Romberg's sign.

Brain involvement causes a range of syndromes, including cognitive and motor impairment, which are sometimes grouped under the broad term 'general paresis'. Features of general paresis may include:

- Personality change
- Memory impairment
- Altered mood
- Confusion
- Seizures
- Tremor
- Argyll-Robertson pupils.

A neurology or psychiatric consultation is required if neurosyphilis or brain involvement is suspected.

Cardiovascular syphilis usually affects the aortic root, causing an aortitis, which results in aortic regurgitation. Angina may arise as a result of coronary ostial stenosis. Aortic medial necrosis may cause aortic aneurysm. The cardiac murmur of aortic regurgitation and/or symptoms and signs of heart failure or aortic aneurysm on clinical examination require a cardiology consultation.

Gummata of syphilis (also known as benign tertiary syphilis) affects skin and visceral organs, causing organomegaly and infiltrative or destructive lesions, as well as perforation or collapse of affected structures. Gumma lesions consist of granulomatous rubbery tissue with a necrotic centre. The destructive lesions may gradually replace normal tissue. Gummata are an extremely rare manifestation of late syphilis, with the most common presentation being chronic skin ulceration and nodular infiltration.
**Syphilis infection**

**Diagnosis**

Syphilis is an important facilitator of HIV transmission. MSM are at particular risk of co-infection with HIV.[21] [31] [32] The presence of HIV may alter the presentation of syphilis.[33]

- Primary syphilis: larger, painful multiple ulcers.
- Secondary syphilis: genital ulcers more common and higher titres with rapid plasma reagin (RPR) testing and Venereal Disease Research Laboratory (VDRL) testing.
- Possibly more rapid progression to neurosyphilis.
- Serological responses to infection may be atypical.[30]

**HIV co-infection**

Signs and symptoms of congenital syphilis

Congenital syphilis occurs when the fetus acquires the infection transplacentally from the mother. This may result in miscarriage, stillbirth, or neonatal death.[2] Intrauterine features such as hydrops may be detected on fetal ultrasound scanning. Postnatal manifestations are divided into early and late stages; early manifestations occur in the first 2 years of life, and late manifestations occur after 2 years of age.

The diagnosis of congenital syphilis is suspected, taking into account various factors, including:[5]

- Identification of syphilis in the mother
- Adequacy of maternal treatment
- Presence of clinical, laboratory, or radiographic evidence of syphilis in the infant (testing should include paired maternal and neonatal non-treponemal serological titres using the same test, preferably conducted at the same laboratory).

Most clinical signs are not visible at birth, but usually develop within 3 months. A highly infectious rhinitis, which may be purulent or blood-stained, may persist and is one of the earliest signs. Other early signs (occurring within 2 years) include hepatosplenomegaly, glomerulonephritis and nephrotic syndrome, generalised lymphadenopathy, central nervous system (CNS) involvement (including cerebrospinal fluid [CSF] abnormalities and syphilitic meningitis), and bone involvement (e.g., osteochondritis).[6] [33] A neonatal skin rash may occur and may be similar to the rash of secondary syphilis in adults. It may also be more widespread, bullous or papulonecrotic, or desquamating. Initially, the rash may be vesicular with small blisters appearing on the palms and plantar surfaces of the feet. An erythematous or maculopapular rash, which is often copper-coloured, may subsequently appear on the face, palms, and plantar surfaces of the feet. Necrotising funisitis (inflammation of the umbilical cord) is virtually diagnostic of congenital syphilis and is found usually in pre-term infants who are stillborn, or die within a few weeks of birth. The umbilical cord has a specific appearance known as the ‘barberpole’ cord as a result of inflammation of the matrix of the umbilical cord.[6] [34]

**Untreated congenital syphilis may present late (after age 2 years). It is important to distinguish late congenital syphilis from postnatally acquired syphilis, as the latter raises the suspicion of child sexual abuse and should be investigated further.[35]**

Late congenital syphilis has several distinct findings, including:[33]
Syphilis Infection

Diagnosis

Interstitial keratitis

CDC/Susan Lindsley

• Interstitial keratitis
• Peg-shaped central incisors, notched at the apex (Hutchinson's teeth)
• Eighth cranial nerve deafness
• Frontal bossing of the skull
• Anterior bowing of the shins (Saber shins)
• Saddle nose deformity
• Clutton's joints (symmetric painless knee swelling).

Interstitial keratitis, Hutchinson's teeth, and eighth cranial nerve deafness are collectively known as Hutchinson's triad.

Initial investigations for acquired syphilis

Microscopic tests:

Culture of *Treponema pallidum* in vitro is not possible. Dark-field microscopy of the skin lesion can provide a definitive diagnosis of syphilis, but this test is not usually available outside specialist settings. The lesion is cleansed and abraded with a gauze pad until serous exudates appear, which are then collected onto a glass slide for microscopic analysis. Identification of *T pallidum* from the sample...
allows for immediate diagnosis. A single negative result does not exclude infection as collection of the treponemes is operator-dependent. A lesion is considered negative for *T. pallidum* if microscopy on three different days is negative.[36] [37] Sensitivity of dark-field microscopy for genital ulcers is 74% to 86% and specificity is 85% to 100%.[36] [38] [39] [40]

For secondary syphilis, dark-field microscopy may be positive from skin or ulcerative anogenital lesions. However, gummata in tertiary syphilis have few, if any, identifiable *T. pallidum* organisms. If available, dark-field microscopy should also be performed on any lesions or nasal discharge in infants with possible congenital syphilis.

Serological tests:

Serology testing is the most commonly used method for diagnosing syphilis. It should be performed in all patients with signs or symptoms of syphilis (e.g., a painless anogenital ulcer). Serology testing requires the use of both treponemal (specific) and non-treponemal (non-specific) tests. The most common approach is to use a treponemal test as the initial serological test, followed by a non-treponemal test if the treponemal test is positive (i.e., a ‘reverse sequence screening algorithm’).[41] This approach reduces time and costs compared with using a non-treponemal test as the initial serology test.[41] [42]

Treponemal tests include:[15]

- Treponemal enzyme immunoassay (EIA)
- *T. pallidum* particle agglutination assay (TPPA)
- *T. pallidum* haemagglutination assay (TPHA)
- Fluorescent antibody absorption (FTA-ABS)
- Immunocapture assay (ICA).

Treponemal tests are antigen-based tests and work by detecting antibodies to *T. pallidum*. A patient with a positive treponemal test result will remain positive for life, irrespective of current or past infection. Therefore, a positive result alone cannot distinguish between an active infection (i.e., currently untreated or incompletely treated) and a past (treated) infection. Another limitation is that false-positive results may occur in the presence of diseases caused by non-sexually transmitted treponemal infections (e.g., yaws, pinta, bejel). False-negative results may occur in incubating and early primary syphilis.[43]

A non-treponemal test should always be undertaken following a positive treponemal test to confirm a diagnosis and provide evidence of active disease or re-infection. Non-treponemal tests include:[5] [44] [45]

- RPR test
- VDRL test

The RPR test is usually the test of choice due to ease of use and interpretation. Non-treponemal tests work by detecting the antibody response to the release of cardiolipin during syphilis infection. These tests can provide a quantitative measure of disease activity (titre) and can be used to monitor treatment response.[46] [47] [48] [49] [50] RPR and VDRL titres decrease or become non-reactive with effective treatment. A titre of ≥32 is rarely seen in adequately treated infection. Despite adequate treatment, some patients maintain a persisting low level positive antibody titre (known as a serofast reaction).[51] False positives may occur due to the presence of a variety of medical conditions, such as pregnancy, autoimmune disorders, and other infections. A false-negative test may occasionally occur in an undiluted specimen (the prozone phenomenon).
If the non-treponemal test is negative, then a different treponemal test should be performed to confirm the results of the initial treponemal test.[5]

The same non-treponemal test should be used sequentially when monitoring treatment response. This is because results obtained from one test are not directly comparable with that of the next non-treponemal test. A fourfold change in titre, equivalent to a change of two dilutions (e.g., from 1:16 to 1:4 or from 1:8 to 1:32), signifies a clinically significant difference between two non-treponemal test results.

There is evidence that the majority of patients with HIV who are treated for syphilis will have persistently positive non-treponemal titres (i.e., they are serofast), despite a fourfold decrease in titres as a result of treatment.

Incubation periods (usual time after infection that the test becomes positive) for treponemal and non-treponemal tests are as follows.

**Treponemal tests**
- **EIA**: 3 weeks
- **TPPA**: 4-6 weeks
- **TPHA**: 4-6 weeks.

**Non-treponemal tests**
- **RPR**: 4 weeks
- **VDRL**: 4 weeks.

Patients with secondary syphilis will have strongly positive syphilis serological tests. Delayed seroreactivity or false-negative non-treponemal serology may rarely occur if there is HIV co-infection.[30][52][53]

Patients with early or late latent syphilis may be detected as part of screening blood tests (e.g., prior to blood donation). EIA is the serological treponemal test generally used for screening.[54] In late latent syphilis, treponemal tests are always positive.

In tertiary syphilis, positive serology will suggest a diagnosis already suspected from the history and clinical signs.

**Other initial investigations for acquired syphilis**

Line immunoassay (LIA) serological tests (e.g., INNO-LIA Syphilis test) can be used to confirm syphilis infection following initial serological treponemal testing. A single LIA test can confirm infection, making it more convenient than traditional methods of serological confirmation, which usually require performing multiple assays. Studies evaluating the performance of LIA tests for syphilis infection have demonstrated higher sensitivity and specificity compared with FTA-ABS and TPHA serology tests.[55][56]

**Emerging investigations**

Compared with current tests (e.g., serology, dark-field microscopy), polymerase chain reaction (PCR) testing for *T pallidum* using samples taken directly from ulcerative lesions has been found to be moderately sensitive (70% to 80%) and highly specific (>90%) for diagnosing primary and secondary syphilis.[57] The CDC considers PCR testing a valid method for diagnosing primary and secondary syphilis, and its use is likely to increase.[58]
Point of care (POC) serological testing with either treponemal or combination treponemal/non-treponemal tests has been assessed in the setting of high-risk regions, where rapid and early diagnosis may be more important than accuracy. Several clinical trials have shown promise[59] and POC testing has been recommended as part of the Pan American Health Organization strategy to diagnose and treat syphilis.[60]

Further investigations for acquired syphilis

A lumbar puncture and CSF examination should be performed in any patient with clinical evidence of neurosyphilis (e.g., headache, meningismus, ophthalmic or auditory symptoms, cranial nerve palsies, motor or sensory deficits, seizures, or cognitive dysfunction).[5] CNS involvement can occur at any stage of syphilis and can range from asymptomatic meningeal involvement to dementia and sensory neuropathy. A computed tomography or magnetic resonance imaging brain scan should be performed first if there is concern regarding raised intracranial pressure (i.e., mainly to ensure that undertaking a lumbar puncture is safe). A lumbar puncture is also indicated if syphilis of unknown duration is diagnosed in the presence of HIV co-infection. Neurosyphilis is suggested by:[29]

- CSF white blood cell (WBC) count >10 cells/mm³ (10 × 10⁶ cells/L)
- CSF protein >50 mg/dL (0.50 g/L)
- A positive CSF VDRL test.

The CSF will also demonstrate a positive TPHA, TPPA, or FTA-ABS treponemal test.[29] [61] [62] [63] A non-reactive CSF-TPHA test result usually excludes neurosyphilis. Neurological involvement is unlikely at CSF TPHA or TPPA titres <1:320. CSF examination should be repeated every 6 months until the CSF WBC count is normal if elevated on the initial sample.

[VIDEO: Diagnostic lumbar puncture in adults: animated demonstration ]

A chest x-ray should be performed in people with syphilis of unknown duration, and in those who have had syphilis for more than 2 years, whether or not they have had cardiac symptoms. This may detect possible aortic aneurysm or aortic calcification. Any patient with suspected aortic regurgitation, heart failure, or aortic aneurysm will require both a chest x-ray and echocardiogram.

All patients with syphilis should be tested for HIV. In geographical areas in which the prevalence of HIV is high, patients who have primary syphilis should be re-tested for HIV after 3 months, even if the first HIV test result is negative.[5] Hence a low threshold for the testing and treatment of syphilis in patients with HIV is advisable.

Initial investigations for congenital syphilis

The CDC has published recommendations concerning serological tests required in the diagnosis of congenital syphilis.[5] Syphilis serology should be performed on all pregnant women at the first antenatal visit.[5] Serology should be repeated again early in the third trimester and at delivery if serology has been positive, or if there is high maternal risk of syphilis acquisition. The syphilis serological status of the mother should be determined during pregnancy and prior to discharge of the infant from hospital.[5] Any woman who delivers a stillborn infant should be tested for syphilis. All pregnant women who have syphilis should also be tested for HIV. All infants who are born to mothers with positive serology require a non-treponemal test (VDRL or RPR), which should be performed on the infant's serum rather than on umbilical cord blood.
Further investigations for congenital syphilis

Pregnant women with syphilis or suspected of having syphilis require a fetal ultrasound scan. The presence of fetal or placental syphilis (e.g., hepatomegaly, ascites, hydrops fetalis) indicates a greater risk of treatment failure for congenital syphilis.[70]

After birth, lumbar puncture with CSF analysis for WBC count, protein (and VDRL), full blood count, and other tests as clinically indicated (e.g., chest x-ray, cranial ultrasound, long-bone x-rays, liver function tests, auditory brainstem response) are recommended by the CDC in the following cases:[5]

- Infants (aged <1 month) with confirmed or highly probable disease plus:
  - An abnormal physical examination that is consistent with congenital syphilis or
  - A serum quantitative non-treponemal serological titre that is fourfold higher than the mother’s titre or
  - A positive dark-field or fluorescent antibody test of body fluid.
- Infants (aged <1 month) who have a normal physical examination and a serum quantitative non-treponemal serological titre the same or less than fourfold the maternal titre plus:
  - The mother was not treated, was inadequately treated, or has no documentation of having received treatment or
  - The mother was treated with erythromycin or other non-penicillin regimen or
  - The mother received treatment <4 weeks before delivery.
- Children aged >1 month with reactive serological tests and at risk of congenital syphilis. These children should also have an HIV test.

Risk factors

Strong

sexual contact with an infected person
- The risk of acquiring syphilis after sex with someone with primary or secondary syphilis is between 30% and 60%. [18] [19]

men who have sex with men (MSM)
- At higher risk, particularly if they are also HIV co-infected, use illicit drugs such as methamphetamine (metamfetamine), or have multiple, casual sexual partners.[21] [22]
- In 2017, more than half (57.9%) of all reported cases of primary and secondary syphilis in the US occurred in MSM.[9]

illicit drug use
- Association due to the exchange of sex for money or drugs, particularly crack cocaine.[23] [24]

commercial sex workers
- Association due to the exchange of sex for money or drugs, particularly crack cocaine.[23] [24]
**multiple sexual partners**
- A risk factor for all STIs.
- Important in syphilis epidemiology.[21]

**people with HIV or other STIs**
- Suggests unprotected sexual intercourse, which increases the risk of STIs.
- All patients who have an STI should have syphilis screening, as should patients at higher risk of STIs, irrespective of where they are seen.

**syphilis during pregnancy (risk for congenital syphilis)**
- The fetus acquires the infection from the infected mother.
- This may result in miscarriage, stillbirth, or a neonatal death.[2]
- Antenatal screening aims to identify and treat asymptomatic infected women, thus preventing transplacental transmission.[25]

### History & examination factors

#### Key diagnostic factors

**presence of risk factors (common)**
- Groups at risk include people who have had sexual contact with an infected person, men who have sex with men, illicit drug users, commercial sex workers, those with multiple sexual partners, and people infected with HIV or other STIs.
- Pregnant women with syphilis are at risk of transmitting the infection transplacentally to the fetus.

**anogenital ulcer (common)**
- Initially a macule, developing into a papule and then ulcerating to form a chancre.
  [Fig-2]
- Classically appears in the anogenital area 14 to 21 days after exposure (primary infection).
- Usually indurated, solitary, and painless.
  [Fig-3]
- May not always be noticed by the patient and examining physician, and it heals spontaneously.
- Atypically, may be multiple and painful. Co-infection with genital herpes or chancroid may cause painful ulceration. HIV co-infection may be associated with multiple ulcers.
- Erosions on the genitalia may also occur in secondary syphilis.
  [Fig-8]

**lymphadenopathy (common)**
- Moderately enlarged, rubbery regional lymphadenopathy associated with the classical syphilitic ulcer (chancre) in primary infection.
- Generalised lymphadenopathy may occur with secondary syphilis.

**diffuse rash (common)**
- Symmetrical macular, papular, or maculopapular rash in secondary syphilis.
  [Fig-5]
  [Fig-7]
Syphilis infection

Diagnosis

- Often widespread with mucous membrane involvement.
- May desquamate.
- Usually non-itchy, over the trunk, palms, soles, and scalp.
- In dark-skinned patients may cause pruritus.
- May accompany a history of constitutional symptoms such as fever and malaise.
- Onset is usually 6 to 12 weeks after exposure.
- Up to 25% of people who have untreated secondary syphilis develop relapsing episodes of rash and fever.
- Rash also occurs in congenital syphilis.

**constitutional symptoms (common)**

- Such as fever, malaise, myalgia, fatigue, and arthralgia with secondary syphilis.
- May be mistaken for primary HIV infection or another intercurrent viral illness.
- Up to 25% of people who have untreated secondary syphilis develop relapsing episodes of rash and fever.

**fatigue (common)**

- As a result of cardiovascular syphilis (tertiary disease), which may lead to heart failure.
- May also be a constitutional symptom in secondary syphilis.

**rhinitis (congenital syphilis) (common)**

- A sign of early congenital syphilis (occurring <2 years of age).
- Discharge may be purulent and bloody.

**hepatosplenomegaly (congenital syphilis) (common)**

- A sign of early congenital syphilis (occurring <2 years of age).
- Usually associated with other signs of disseminated infection (rash, mucous membrane ulceration).

**patchy alopecia (uncommon)**

- May develop in secondary syphilis.

**condylomata lata (uncommon)**

- Slightly raised, or flat, round, or oval papules covered by grey exudates.
- A sign of secondary syphilis.
- May be present within moist areas of the perineum.
- May be mistaken for genital warts.

**memory impairment, altered mood, confusion, or dementia (uncommon)**

- Possible signs of neurosyphilis.
- Brain involvement in tertiary syphilis causes a range of syndromes, including cognitive and motor impairment, which are sometimes grouped under the broad term 'general paresis'.

**visual disturbance (uncommon)**

- Visual impairment may be a presenting feature of syphilitic iritis or uveitis, occurring in secondary infection.

**Argyll-Robertson pupils (uncommon)**
• Bilaterally small, irregular pupils, which do not constrict when exposed to bright light, but do constrict in response to accommodation.
• A feature of tabes dorsalis occurring in tertiary syphilis.

**loss of sense of vibration, proprioception, and position sense (uncommon)**

• Dorsal column loss is a feature of tabes dorsalis, occurring in tertiary syphilis.

**ataxia (uncommon)**

• A feature of tabes dorsalis occurring in tertiary syphilis.

**loss of anal and bladder sphincter control (uncommon)**

• A feature of tabes dorsalis occurring in tertiary syphilis.

**positive Romberg's sign (uncommon)**

• A feature of tabes dorsalis occurring in tertiary syphilis.

**diastolic murmur (uncommon)**

• Possible sign of cardiovascular syphilis (tertiary disease).
• Diastolic murmur at the left sternal edge indicates aortic regurgitation, which may be due to aortitis caused by cardiovascular syphilis.

**rubbery lesions/nodules with a necrotic centre (uncommon)**

• A sign of gummatous syphilis (also known as benign tertiary syphilis).
• Affects skin and visceral organs.
• The destructive gumma may gradually replace normal tissue.

**miscarriage, stillbirth, or neonatal death (congenital syphilis) (uncommon)**

• Signs of congenital syphilis.[71]

**premature labour and intrauterine growth retardation (congenital syphilis) (uncommon)**

• Signs of early congenital syphilis.

**neonatal skin rash (congenital syphilis) (uncommon)**

• May occur in early congenital syphilis (occurring <2 years of age).
• This rash may be similar to the rash of secondary syphilis in adults. It may also be more widespread, bullous or papulonecrotic, or desquamating.
• Initially the rash may be a vesicular rash with small blisters appearing on the palms and plantar surfaces of the feet. An erythematous or maculopapular rash, which is often copper-coloured, may subsequently appear on the face, palms, and plantar surfaces of the feet. The rash may also affect the mouth, genitalia, and anus.
  [Fig-9]

  [Fig-10]

**tibial bowing (congenital syphilis) (uncommon)**

• A sign of late congenital syphilis (occurring >2 years of age).
• Due to neonatal osteochondritis in congenital syphilis.
Syphilis infection

Diagnosis

craniofacial malformation (congenital syphilis) (uncommon)
- A sign of late congenital syphilis (occurring >2 years of age).
- Including frontal bossing, high cranium, and saddle nose.

tooth abnormalities (congenital syphilis) (uncommon)
- A sign of late congenital syphilis (occurring >2 years of age).
- Hutchinson’s teeth (peg-shaped incisors, notched at the apex), mulberry molars dome-shaped with small cusps at the apex.
- Poorly mineralised teeth.

necrotising funisitis (congenital syphilis) (uncommon)
- Necrotising funisitis (inflammation of the umbilical cord) is virtually diagnostic of congenital syphilis. Usually found in pre-term infants who are stillborn or die within a few weeks of birth.
- The umbilical cord has a specific appearance known as the ‘barberpole’ cord as a result of inflammation of the matrix of the umbilical cord.[6] [34]

Other diagnostic factors

mouth ulcer (common)
- May co-exist with genital ulceration.
- Occurs in both primary and secondary infection.
- In secondary infection the mouth ulcers (snail track ulcers) will usually be co-existent with other symptoms or signs, such as rash, fever.

asymptomatic with positive serology (latent syphilis) (common)
- Latent syphilis is defined as positive serology in the absence of clinical features of syphilis.
- Ulcers in primary syphilis may not be noticed by the patient and examining physician.

tremor (uncommon)
- Possible sign of tertiary disease with brain involvement.
- Brain involvement in tertiary syphilis causes a range of syndromes, including cognitive and motor impairment, which are sometimes grouped under the broad term ‘general paresis’.

headache (uncommon)
- May indicate neurological involvement.
- May occur with neck stiffness.

meningismus (uncommon)
- May indicate neurological involvement.

eye pain (uncommon)
- May be a presenting feature of syphilitic iritis or uveitis, occurring in secondary infection.

hearing loss (uncommon)
- The eighth cranial nerve is the most commonly affected cranial nerve in neurosyphilis.
• Hearing loss may be a symptom and a sign of both early and late neurosyphilis.
• Deafness may also occur as a result of late congenital syphilis (occurring >2 years of age).

**seizures (uncommon)**
• Suggest neurological involvement.

**peripheral oedema (uncommon)**
• Occurs with nephrotic syndrome that may develop due to vasculitis in secondary syphilis.

**jaundice (uncommon)**
• May indicate hepatitis, due to vasculitis in secondary syphilis.

**peripheral neuropathy (uncommon)**
• Sign of neurosyphilis.
• Usually affecting lower limbs.

**areflexia (uncommon)**
• May occur in all forms of neurosyphilis.

**angina (uncommon)**
• As a result of cardiovascular syphilis (tertiary disease).

**dyspnoea (uncommon)**
• As a result of cardiovascular syphilis (tertiary disease), which may lead to heart failure.
• Aortic aneurysm caused by syphilis almost always affects the thoracic aorta (usually the ascending part of the thoracic aorta), resulting in heart failure.

**organomegaly (uncommon)**
• Lesions in gummatous syphilis may cause organomegaly, and become infiltrative or destructive.

**skin or visceral organ perforation or collapse of structure (uncommon)**
• May occur as a result of gummatous syphilis.

**neonatal neurological abnormalities (congenital syphilis) (uncommon)**
• May include a wide range of problems such as seizures, meningitis, obstructive hydrocephalus, and cranial nerve palsies.
# Diagnostic tests

## 1st test to order

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>dark-field microscopy of swab from lesion</strong></td>
<td>coiled spirochaete bacterium with a corkscrew appearance and motility</td>
</tr>
<tr>
<td>• Performed to identify <em>Treponema pallidum</em>.</td>
<td></td>
</tr>
<tr>
<td>• Can provide a definitive diagnosis of syphilis, but is not usually available outside specialist settings.</td>
<td></td>
</tr>
<tr>
<td>• The lesion is cleansed and abraded with a gauze pad until serous exudates appear, which are collected onto a glass slide for microscopic analysis.</td>
<td></td>
</tr>
<tr>
<td>• A single negative result does not exclude infection; ideally 3 negative examinations on different days are required.</td>
<td></td>
</tr>
<tr>
<td>• Primary syphilis: sensitivity of dark-field microscopy is 74% to 86%, specificity is 85% to 100%.</td>
<td>[38]</td>
</tr>
<tr>
<td>• Secondary syphilis: dark-field microscopy may be positive from ulcerative anogenital lesions.</td>
<td></td>
</tr>
<tr>
<td>• Gummata in tertiary syphilis have few, if any, identifiable <em>T. pallidum</em> organisms.</td>
<td></td>
</tr>
<tr>
<td><strong>serum treponemal enzyme immunoassay (EIA)</strong></td>
<td>positive</td>
</tr>
<tr>
<td>• A treponemal serology test.</td>
<td></td>
</tr>
<tr>
<td>• A patient with a positive treponemal test result will remain positive for life. Therefore, a positive result alone cannot distinguish between an active infection or past (treated) infection.</td>
<td></td>
</tr>
<tr>
<td>• The most common approach is to use a treponemal test as the initial serological test, followed by a non-treponemal test to confirm diagnosis and provide evidence of active disease or re-infection (i.e., a “reverse sequence screening algorithm”).</td>
<td>[41]</td>
</tr>
<tr>
<td>• False-positive results may occur with other non-sexually transmitted treponemal infection (e.g., yaws, pinta, bejel).</td>
<td></td>
</tr>
<tr>
<td>• False-negative results may occur in incubating and early primary syphilis. It usually takes 3 weeks for an EIA IgG/IgM test to become positive after infection with <em>Treponema pallidum</em>.</td>
<td></td>
</tr>
<tr>
<td>• EIA is the test generally used for screening.</td>
<td>[3]</td>
</tr>
<tr>
<td>• Primary syphilis: EIA sensitivity 82% to 100%, and specificity 97% to 100%.</td>
<td>[72]</td>
</tr>
<tr>
<td>• Secondary syphilis: EIA sensitivity is 100%.</td>
<td>[72]</td>
</tr>
<tr>
<td>• Late latent syphilis: EIA sensitivity is 98% to 100%.</td>
<td>[72]</td>
</tr>
<tr>
<td><strong>serum Treponema pallidum particle agglutination (TPPA)</strong></td>
<td>positive</td>
</tr>
<tr>
<td>• A treponemal serology test.</td>
<td></td>
</tr>
<tr>
<td>• A patient with a positive treponemal test result will remain positive for life. Therefore, a positive result alone cannot distinguish between an active infection or past (treated) infection.</td>
<td></td>
</tr>
<tr>
<td>• The most common approach is to use a treponemal test as the initial serological test, followed by a non-treponemal test to confirm diagnosis and provide evidence of active disease or re-infection (i.e., a “reverse sequence screening algorithm”).</td>
<td>[41]</td>
</tr>
<tr>
<td>• Primary syphilis: TPPA sensitivity 85% to 100%, and specificity 98% to 100%.</td>
<td>[73] [74]</td>
</tr>
<tr>
<td>• Secondary and late latent syphilis: TPPA sensitivity 98% to 100%.</td>
<td>[74]</td>
</tr>
<tr>
<td><strong>serum Treponema pallidum haemagglutination (TPHA)</strong></td>
<td>positive</td>
</tr>
<tr>
<td>• A treponemal serology test.</td>
<td></td>
</tr>
</tbody>
</table>
### Test

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>serum fluorescent treponemal antibody absorption (FTA-ABS) test</strong></td>
<td>positive</td>
</tr>
<tr>
<td>• A treponemal serology test.</td>
<td></td>
</tr>
<tr>
<td>• A patient with a positive treponemal test result will remain positive for life. Therefore, a positive result alone cannot distinguish between an active infection or past (treated) infection.</td>
<td></td>
</tr>
<tr>
<td>• The most common approach is to use a treponemal test as the initial serological test, followed by a non-treponemal test to confirm diagnosis and provide evidence of active disease or re-infection (i.e., a 'reverse sequence screening algorithm').[75]</td>
<td></td>
</tr>
<tr>
<td>• FTA-ABS is used less often than TPHA and TPPA because it is less specific.</td>
<td></td>
</tr>
<tr>
<td><strong>immunocapture assay</strong></td>
<td>positive</td>
</tr>
<tr>
<td>• A treponemal serology test.</td>
<td></td>
</tr>
<tr>
<td>• A patient with a positive treponemal test result will remain positive for life. Therefore, a positive result alone cannot distinguish between an active infection or past (treated) infection.</td>
<td></td>
</tr>
<tr>
<td>• The most common approach is to use a treponemal test as the initial serological test, followed by a non-treponemal test to confirm diagnosis and provide evidence of active disease or re-infection (i.e., a 'reverse sequence screening algorithm').[75]</td>
<td></td>
</tr>
<tr>
<td><strong>line immunoassay (LIA) serological test</strong></td>
<td>positive</td>
</tr>
<tr>
<td>• A treponemal serology test.</td>
<td></td>
</tr>
<tr>
<td>• A patient with a positive treponemal test result will remain positive for life. Therefore, a positive result alone cannot distinguish between an active infection or past (treated) infection.</td>
<td></td>
</tr>
<tr>
<td>• LIA serological tests (e.g., INNO-LIA syphilis test) can be used to confirm syphilis infection following initial serological treponemal testing. A single LIA test can confirm infection, making it more convenient than traditional methods of serological confirmation (which usually require multiple assays). Studies evaluating the performance of LIA tests for syphilis infection have demonstrated higher sensitivity and specificity compared with FTA-ABS and TPHA serology tests.[55][56]</td>
<td></td>
</tr>
<tr>
<td><strong>serum rapid plasma reagin (RPR) test</strong></td>
<td>positive</td>
</tr>
<tr>
<td>• A non-treponemal serology test.</td>
<td></td>
</tr>
<tr>
<td>• Provides a quantitative measure of disease activity and can be used to monitor treatment response (RPR titers decrease or become non-reactive with effective treatment).</td>
<td></td>
</tr>
<tr>
<td>• The most common approach is to use a treponemal test as the initial serological test, followed by a non-treponemal test to confirm diagnosis and provide evidence of active disease or re-infection (i.e., a 'reverse sequence screening algorithm').[75]</td>
<td></td>
</tr>
<tr>
<td>• A titre of ≥32 is rarely seen in adequately treated infection.</td>
<td></td>
</tr>
<tr>
<td>• Despite adequate treatment, some patients maintain a persisting low level positive antibody titre (known as a serofast reaction).[51]</td>
<td></td>
</tr>
</tbody>
</table>
Syphilis infection

### Diagnosis

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>• False positives may occur due to the presence of a variety of medical conditions (e.g., pregnancy, autoimmune disorders, and infections).</td>
<td></td>
</tr>
<tr>
<td>• A false-negative test may occasionally occur in an undiluted specimen (the prozone phenomenon).</td>
<td></td>
</tr>
<tr>
<td>• Primary syphilis: RPR sensitivity 70% to 73%.</td>
<td></td>
</tr>
<tr>
<td>• Secondary syphilis: RPR sensitivity is 100%.</td>
<td></td>
</tr>
<tr>
<td>• Preferred test over the serum Venereal Disease Research Laboratory test.</td>
<td></td>
</tr>
<tr>
<td>serum Venereal Disease Research Laboratory (VDRL) test</td>
<td>positive</td>
</tr>
<tr>
<td>• A non-treponemal serology test.</td>
<td></td>
</tr>
<tr>
<td>• Provides a quantitative measure of disease activity and can be used to monitor treatment response (VDRL titres decrease or become non-reactive with effective treatment).</td>
<td></td>
</tr>
<tr>
<td>• The most common approach is to use a treponemal test as the initial serological test, followed by a non-treponemal test to confirm diagnosis and provide evidence of active disease or re-infection (i.e., a 'reverse sequence screening algorithm').</td>
<td></td>
</tr>
<tr>
<td>• A titre of $\geq 32$ is rarely seen in adequately treated infection.</td>
<td></td>
</tr>
<tr>
<td>• Despite adequate treatment, some patients maintain a persisting low level positive antibody titre (known as a serofast reaction).</td>
<td></td>
</tr>
<tr>
<td>• False positives may occur due to the presence of a variety of medical conditions (e.g., pregnancy, autoimmune disorders, and infections).</td>
<td></td>
</tr>
<tr>
<td>• A false-negative test may occasionally occur in an undiluted specimen (the prozone phenomenon).</td>
<td></td>
</tr>
<tr>
<td>• Primary syphilis: VDRL sensitivity 44% to 76%.</td>
<td></td>
</tr>
<tr>
<td>• VDRL is positive in 77% of cases of late latent syphilis.</td>
<td></td>
</tr>
<tr>
<td>• VDRL sensitivity in secondary syphilis is 100%.</td>
<td></td>
</tr>
</tbody>
</table>
### Other tests to consider

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>lumbar puncture, cerebrospinal fluid (CSF) analysis</strong></td>
<td>WBC count &gt;10 cells/mm³; CSF protein &gt;50 mg/dL (0.50 g/L); CSF VDRL positive; CSF TPHA/TPPA/FTA-ABS positive</td>
</tr>
<tr>
<td>• Indicated for any patient with clinical evidence of neurological involvement (e.g., cognitive dysfunction, motor or sensory deficits, ophthalmic or auditory symptoms, cranial nerve palsy, features of meningitis).</td>
<td></td>
</tr>
<tr>
<td>• Indicated if syphilis of unknown duration exists in the presence of HIV co-infection.</td>
<td></td>
</tr>
<tr>
<td>• Indicated in any child with congenital syphilis and neurological symptoms or signs.[5]</td>
<td></td>
</tr>
<tr>
<td>• An elevated CSF WBC count and positive CSF Venereal Disease Research Laboratory (VDRL) suggests neurological involvement.[29]</td>
<td></td>
</tr>
<tr>
<td>• Some patients with neurosyphilis have an isolated elevated CSF WBC count and negative rapid plasma reagin/VDRL.</td>
<td></td>
</tr>
<tr>
<td>• Neurosyphilis is unlikely at CSF Treponema pallidum haemagglutination assay (TPHA)/ T pallidum particle agglutination assay (TPPA) titres &lt;1:320.</td>
<td></td>
</tr>
<tr>
<td>• A non-reactive CSF-TPHA test result usually excludes neurosyphilis.</td>
<td></td>
</tr>
<tr>
<td>• [VIDEO: Diagnostic lumbar puncture in adults: animated demonstration ]</td>
<td></td>
</tr>
<tr>
<td><strong>chest x-ray</strong></td>
<td>possible widened thoracic aorta, aortic calcification</td>
</tr>
<tr>
<td>• May detect possible thoracic aortic aneurysm or aortic calcification.</td>
<td></td>
</tr>
<tr>
<td>• Required in people with symptoms or signs of aortic regurgitation, heart failure, or aortic aneurysm.</td>
<td></td>
</tr>
<tr>
<td><strong>echocardiogram</strong></td>
<td>may show evidence of heart failure, aortic regurgitation, or thoracic aortic aneurysm</td>
</tr>
<tr>
<td>• Required if cardiovascular syphilis is strongly suspected (e.g., a patient has symptoms or signs of aortic regurgitation, heart failure, or aortic aneurysm).</td>
<td></td>
</tr>
<tr>
<td><strong>CT brain</strong></td>
<td>usually normal</td>
</tr>
<tr>
<td>• Performed before lumbar puncture to exclude elevated intracranial pressure, to ensure that undertaking a lumbar puncture will be safe.</td>
<td></td>
</tr>
<tr>
<td>• Elevated intracranial pressure is rarely caused by syphilis itself.</td>
<td></td>
</tr>
<tr>
<td><strong>MRI brain</strong></td>
<td>usually normal</td>
</tr>
<tr>
<td>• Performed before lumbar puncture to exclude elevated intracranial pressure, to ensure that undertaking a lumbar puncture will be safe.</td>
<td></td>
</tr>
<tr>
<td>• Elevated intracranial pressure is rarely caused by syphilis itself.</td>
<td></td>
</tr>
<tr>
<td><strong>HIV test</strong></td>
<td>positive or negative</td>
</tr>
<tr>
<td>• All patients with syphilis should be tested for HIV.</td>
<td></td>
</tr>
<tr>
<td>• In geographical areas in which the prevalence of HIV is high, patients who have primary syphilis should be re-tested for HIV after 3 months even if the first HIV test result is negative.[5]</td>
<td></td>
</tr>
<tr>
<td><strong>fetal ultrasound scan</strong></td>
<td>may show hepatomegaly, ascites, hydrops fetalis, intrauterine growth retardation</td>
</tr>
<tr>
<td>• Should be performed on all pregnant women with syphilis or suspected of having syphilis.</td>
<td></td>
</tr>
<tr>
<td>• Presence of fetal or placental syphilis indicates a greater risk of treatment failure for congenital syphilis.[70]</td>
<td></td>
</tr>
<tr>
<td><strong>FBC</strong></td>
<td>may show anaemia, thrombocytopenia,</td>
</tr>
<tr>
<td>• Performed in infants with possible congenital syphilis.</td>
<td></td>
</tr>
</tbody>
</table>
### Syphilis infection

#### Diagnosis

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Test</strong></td>
<td><strong>Result</strong></td>
</tr>
<tr>
<td><strong>leukopenia, possible</strong></td>
<td><strong>neutrophilia</strong></td>
</tr>
<tr>
<td><strong>neutrophilia</strong></td>
<td><strong>may demonstrate</strong></td>
</tr>
<tr>
<td><strong>cranial ultrasound</strong></td>
<td><strong>craniofacial malformation</strong></td>
</tr>
<tr>
<td>• May be indicated in infants</td>
<td>• May be indicated in infants</td>
</tr>
<tr>
<td>• Performed if cranial</td>
<td>• Performed if cranial</td>
</tr>
<tr>
<td>abnormalities suspected.</td>
<td>abnormalities suspected.</td>
</tr>
<tr>
<td><strong>long-bone x-rays</strong></td>
<td><strong>may demonstrate</strong></td>
</tr>
<tr>
<td>• May be indicated in infants</td>
<td>• May be indicated in infants</td>
</tr>
<tr>
<td>• Performed if osteochondritis</td>
<td>• Performed if osteochondritis</td>
</tr>
<tr>
<td><strong>may demonstrate</strong></td>
<td><strong>osteochondritis</strong></td>
</tr>
<tr>
<td><strong>liver function tests</strong></td>
<td><strong>may demonstrate</strong></td>
</tr>
<tr>
<td>• May be indicated in infants</td>
<td>• May be indicated in infants</td>
</tr>
<tr>
<td>• Performed if clinical</td>
<td>• Performed if clinical</td>
</tr>
<tr>
<td>findings suggestive of liver</td>
<td>findings suggestive of liver</td>
</tr>
<tr>
<td>involvement (e.g., hepatomegaly).</td>
<td>involvement (e.g., hepatomegaly).</td>
</tr>
<tr>
<td><strong>aspartate aminotransferase</strong></td>
<td><strong>aminotransferase and</strong></td>
</tr>
<tr>
<td>and alanine aminotransferase</td>
<td><strong>alanotransferase may be elevated</strong></td>
</tr>
<tr>
<td>may be elevated**</td>
<td><strong>may detect deafness</strong></td>
</tr>
<tr>
<td><strong>evoked auditory potentials</strong></td>
<td><strong>may detect deafness</strong></td>
</tr>
<tr>
<td>• May be indicated in infants</td>
<td>• May be indicated in infants</td>
</tr>
<tr>
<td>• Performed if clinically</td>
<td>• Performed if clinically</td>
</tr>
<tr>
<td>indicated.</td>
<td>indicated.</td>
</tr>
<tr>
<td><strong>audiometry</strong></td>
<td><strong>may detect hearing deficit</strong></td>
</tr>
<tr>
<td>• Neurosyphilis may involve</td>
<td>• Neurosyphilis may involve</td>
</tr>
<tr>
<td>cranial nerves (particularly</td>
<td>cranial nerves (particularly</td>
</tr>
<tr>
<td>the 8th cranial nerve).</td>
<td>the 8th cranial nerve).</td>
</tr>
</tbody>
</table>

### Emerging tests

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treponema pallidum polymerase chain reaction (PCR) (sample</strong></td>
<td><strong>positive</strong></td>
</tr>
<tr>
<td><strong>taken directly from ulcerative lesions)</strong></td>
<td><strong>Treponema pallidum PCR has been shown to have moderate sensitivity</strong></td>
</tr>
<tr>
<td>• T. pallidum PCR has been shown to have moderate sensitivity (70%</td>
<td>• T. pallidum PCR has been shown to have moderate sensitivity (70%</td>
</tr>
<tr>
<td>to 80%) and high specificity &gt;90% in the diagnosis of primary or</td>
<td>to 80%) and high specificity &gt;90% in the diagnosis of primary or</td>
</tr>
<tr>
<td>secondary syphilis, when compared with adequate reference tests</td>
<td>secondary syphilis, when compared with adequate reference tests</td>
</tr>
<tr>
<td>(e.g., serology, dark-field microscopy). [57]</td>
<td>(e.g., serology, dark-field microscopy). [57]</td>
</tr>
<tr>
<td>• The US Centers for Disease Control and Prevention considers PCR</td>
<td>• The US Centers for Disease Control and Prevention considers PCR</td>
</tr>
<tr>
<td>testing a valid method for diagnosing primary and secondary syphilis,</td>
<td>testing a valid method for diagnosing primary and secondary syphilis,</td>
</tr>
<tr>
<td>and its use is likely to increase. [58]</td>
<td>and its use is likely to increase. [58]</td>
</tr>
<tr>
<td><strong>point of care (POC) testing with either treponemal or</strong></td>
<td><strong>positive; however,</strong></td>
</tr>
<tr>
<td><strong>combination treponemal/non-treponemal antibody</strong></td>
<td><strong>a positive result for treponemal antibodies alone does not</strong></td>
</tr>
<tr>
<td>• POC syphilis testing has been assessed in the setting of high-risk</td>
<td>• POC syphilis testing has been assessed in the setting of high-risk</td>
</tr>
<tr>
<td>regions, where rapid and early diagnosis may be more important than</td>
<td>regions, where rapid and early diagnosis may be more important than</td>
</tr>
<tr>
<td>accuracy. Several clinical trials have shown promise[59] and POC</td>
<td>accuracy. Several clinical trials have shown promise[59] and POC</td>
</tr>
<tr>
<td>testing has been recommended as part of the Pan American Health</td>
<td>testing has been recommended as part of the Pan American Health</td>
</tr>
<tr>
<td>Organization strategy to diagnose and treat syphilis. [60]</td>
<td>Organization strategy to diagnose and treat syphilis. [60]</td>
</tr>
</tbody>
</table>
## Differential diagnosis

<table>
<thead>
<tr>
<th>Condition</th>
<th>Differentiating signs / symptoms</th>
<th>Differentiating tests</th>
</tr>
</thead>
</table>
| **Genital herpes**         | • There may be a history of fever, genital blisters or sores, and lymphadenopathy with first-episode herpes simplex.  
• The patient may describe previous episodes of genital ulceration.  
• On physical examination there are typically multiple, painful vesicular or ulcerative lesions on or around the genitals or rectum. | • Isolation of herpes simplex virus (HSV) from lesions in cell culture confirms the diagnosis, although the sensitivity is low, and decreases as lesions heal.  
Viral culture isolates will identify if HSV-1 or HSV-2 is causative.[5]  
Increasingly, polymerase chain reaction is supplanting culture as the test of choice to diagnose and type HSV. |
| **Chancroid**              | • Characterised by painful genital ulcers and painful inguinal lymphadenopathy. Lesions of primary syphilis are typically not painful.  
• Usually occurs in discrete outbreaks.  
• On physical examination there may be an erythematous papule, pustule, or painful ulcer, as well as painful unilateral inguinal lymphadenopathy (bubo formation), which may rupture. | • *Haemophilus ducreyi* is identified on specialist culture medium, which is not widely commercially available and has a sensitivity of <80%.[77]  
Polymerase chain reaction testing is up to 100% sensitive but is not universally approved.[77][78]  
Therefore a positive diagnosis of chancroid is suggested by the presence of painful genital ulcers with no evidence of syphilis or herpes simplex virus.[5] |
| **Primary HIV infection**  | • Not preceded by genital ulceration.  
• However, genital ulceration may be present at the same time as primary HIV infection and the rash associated with the ulceration. | • Laboratory tests positive for HIV, including antigen (P24 antigen) tests. |
| **Other acute viral exanthemas** | • Not preceded by genital ulceration. | • Laboratory tests positive for specific virus. |
| **Scabies**                | • Skin lesions usually pruritic.  
• Typical distribution: interdigital, wrists, nipples, ankles, buttocks. | • Diagnosis is usually clinical, but skin scrapings and microscopy for *Sarcoptes scabiei* may be performed. |
| **Eczema**                 | • Skin lesions usually absent on palms and plantar aspects of feet. | • Diagnosis is usually clinical.  
Skin biopsy can be undertaken to confirm diagnosis. |
<table>
<thead>
<tr>
<th>Condition</th>
<th>Differentiating signs / symptoms</th>
<th>Differentiating tests</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Psoriasis</strong></td>
<td>• Skin lesions usually absent on palms and plantar aspects of feet.</td>
<td>• Diagnosis is usually clinical.</td>
</tr>
<tr>
<td></td>
<td>• Not associated with signs of systemic infection.</td>
<td>• Skin biopsy can be undertaken to confirm diagnosis.</td>
</tr>
<tr>
<td><strong>Lichen planus</strong></td>
<td>• Skin lesions usually absent on palms and plantar aspect of feet.</td>
<td>• Diagnosis is usually clinical.</td>
</tr>
<tr>
<td></td>
<td>• Not associated with signs of systemic infection.</td>
<td>• Skin biopsy can be undertaken to confirm diagnosis.</td>
</tr>
<tr>
<td><strong>Genital warts</strong></td>
<td>• Pink lumps, in genital and/or peri-anal skin and mucous membranes. Not necessarily confined</td>
<td>• Diagnosis is usually clinical.</td>
</tr>
<tr>
<td></td>
<td>to opposing membranes.</td>
<td>• Exclusion of syphilis (negative syphilis serology).</td>
</tr>
<tr>
<td></td>
<td>• Not associated with other signs of secondary syphilis (rash, constitutional symptoms,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>generalised lymphadenopathy).</td>
<td></td>
</tr>
<tr>
<td><strong>Alzheimer’s dementia</strong></td>
<td>• Progressive dementia.</td>
<td>• Exclusion of syphilis (negative syphilis serology).</td>
</tr>
<tr>
<td></td>
<td>• No specific differentiating symptoms and signs compared with neurosyphilis.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Less likely to have a history of possible signs and symptoms of earlier stages of syphilis</td>
<td></td>
</tr>
<tr>
<td><strong>Vascular dementia</strong></td>
<td>• Progressive dementia.</td>
<td>• Exclusion of syphilis (negative syphilis serology).</td>
</tr>
<tr>
<td></td>
<td>• Multi-infarct dementia often associated with other evidence of arteriopathy.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Less likely to have a history of possible signs and symptoms of earlier stages of syphilis</td>
<td></td>
</tr>
</tbody>
</table>
Step-by-step treatment approach

The treatment of syphilis infection is curative with appropriate antibiotics. Prompt diagnosis and antibiotic therapy is important because of the possibility of long-term complications, either from untreated infection or from prolonged infection of unknown duration. Parenteral benzylpenicillin is the first-line drug treatment for all stages of syphilis, as recommended by the US Centers for Disease Control and Prevention (CDC).[5] The preparation (i.e., benzathine, procaine, aqueous), dose, and length of treatment are determined by the stage and clinical manifestations of the disease.[5] [3] [95] [96]

Without neurosyphilis

Treatment may follow diagnostic test results or may be empirical. Empirical therapy may be considered in those with suspected early infection (a rash or ulceration) before results of serology are available. This approach may be appropriate if there are concerns regarding re-attendance. Sexual contacts of patients with confirmed syphilis should be screened and offered presumptive treatment if follow-up may be problematic. The benefits of empirical therapy (prompt therapy) and risks (potentially unnecessary treatment) should be discussed with the patient.

The first-line treatment for primary, secondary, and early latent syphilis (without neurosyphilis) is intramuscular benzathine benzylpenicillin as a single dose.[5] If the patient is allergic to penicillin and is not pregnant, oral doxycycline may be offered as a first-line treatment. Adherence and patient compliance may influence treatment outcome if oral therapy is administered. Single-dose azithromycin is used in some centres, but is not recommended by the CDC due to concerns regarding macrolide resistance.[97] [98] [99]

Treatment of latent syphilis is intended to prevent late complications. The first-line treatment of late latent and tertiary (gummatous and cardiovascular) syphilis (without neurosyphilis) is intramuscular benzathine benzylpenicillin given as three doses over 2 weeks (days 0, 7, 14). Oral doxycycline may be offered as a first-line treatment to patients with penicillin allergy. Patients who have symptomatic gummatous syphilis or cardiovascular syphilis should undergo cerebrospinal fluid (CSF) examination before treatment is started.

Untreated cardiovascular (latent) syphilis may be asymptomatic, or cause aortic aneurysm (mainly thoracic), aortic regurgitation, angina, or stenosis of coronary ostia. Antibiotic therapy for cardiovascular syphilis does not reverse cardiovascular disease, which may continue to progress after treatment. This is because the underlying pathology of medial necrosis of the aortic wall has been established. Discussion with a cardiologist is advised.

Neurosyphilis

Central nervous system involvement can occur at any stage of syphilis, and can range from asymptomatic meningeal involvement to dementia and sensory neuropathy. First-line treatment for neurosyphilis is intravenous aqueous benzylpenicillin. Second-line treatment is intramuscular procaine benzylpenicillin plus oral probenecid. Some specialists administer intramuscular benzathine benzylpenicillin once weekly for up to 3 weeks after the treatment regimen for neurosyphilis has been completed, to ensure that the duration of treatment is comparable with that of late syphilis in the absence of neurosyphilis.

Penicillin desensitisation is recommended for all patients with penicillin hypersensitivity and neurosyphilis. The evidence for the use of non-penicillin regimens is relatively weak. However, high-dose doxycycline is used by some clinicians in this situation.[100]
Syphilis infection

Penicillin allergy skin testing identifies patients at high risk for penicillin reactions. Skin reagents used should include major and minor allergens.[101] Patients who are skin-test negative can receive penicillin therapy. However, some clinicians perform desensitisation without skin testing, particularly if the skin reagents for both minor and major determinants of penicillin allergy are not available. Acute desensitisation can be performed in patients who have a positive skin test to one of the penicillin determinants, and should be performed in a hospital setting. Oral or intravenous desensitisation can be performed, and is usually completed in 4 hours, following which the first dose of penicillin is administered.[102]

Infection in pregnancy

Parenteral benzylpenicillin is the only recommended treatment in pregnancy. Pregnant patients who are allergic to penicillin should be desensitised and treated with penicillin. Pregnant women should receive penicillin-based treatment according to their stage of syphilis, although some specialists recommend that women presenting in the third trimester with early syphilis should receive two injections of benzathine benzylpenicillin rather than one.

Sonographic fetal assessment for congenital syphilis is performed. The presence of fetal or placental syphilis (e.g., hepatomegaly, ascites, and hydrops fetalis) indicates a greater risk of treatment failure for congenital syphilis.[70] Pregnant women should be advised of the possibility of the Jarisch-Herxheimer reaction. Jarisch-Herxheimer reaction may be complicated by fetal distress and premature labour. Specialist care by an obstetrician is recommended.

Co-infection with HIV

Syphilis is an important facilitator of HIV transmission. Most clinicians treat HIV-positive and HIV-negative patients with the same penicillin regimens, according to the stage of syphilis. For example, first-line treatment of primary and secondary syphilis among patients with HIV co-infection is with a single dose of intramuscular benzathine benzylpenicillin.[5] However, duration of therapy may be prolonged in patients with HIV and neurosyphilis.

People with HIV infection and primary or secondary syphilis should be assessed clinically and serologically for treatment failure at 3, 6, 9, 12, and 24 months after therapy.[5] Although of unconfirmed benefit, some specialists recommend performing CSF analysis 6 months after therapy either routinely or if non-treponemal titres do not decrease fourfold within 6-12 months of therapy. Patients with primary or secondary syphilis and HIV co-infection who are allergic to penicillin should receive antibiotic therapy as recommended for penicillin-allergic, HIV-negative patients.

Congenital syphilis

All infants born to mothers with reactive non-treponemal and treponemal tests should have non-treponemal serology (Venereal Disease Research Laboratory [VDRL] or rapid plasma reagin [RPR] tests) performed on infant serum. False-positive results may occur if umbilical cord blood is sampled, due to contamination of umbilical cord blood with maternal blood.

When infants aged >1 month test positive for syphilis, clinicians should review maternal records and serology results to determine if the infection is congenital or acquired.[5]

If there is evidence of effective treatment (and no re-infection) of the mother, a normal physical examination of the infant, and the infant’s VDRL/RPR is less than fourfold higher than the mother’s, then
no treatment is indicated. Infants with an abnormal physical examination or a VDRL/RPR that is fourfold or greater than the mother's titre should be fully evaluated and treated.

First-line treatment of congenital syphilis is intravenous aqueous benzylpenicillin or intramuscular procaine benzylpenicillin.[5] Intramuscular benzathine benzylpenicillin is recommended if a non-treponemal test in the infant is non-reactive and there is low likelihood of infectivity.[5] Discussion with an obstetric specialist and neonatologist is recommended. Intramuscular benzathine benzylpenicillin is infrequently used in resource-rich countries. Close clinical and serological follow-up by a paediatric specialist is recommended.

**Potential adverse effects of therapy**

Patients should be warned of possible reactions to treatment, such as the Jarisch-Herxheimer reaction and iatrogenic procaine reaction.

Jarisch-Herxheimer reaction is an acute febrile illness that can occur within the first 24 hours after initiation of antibiotic treatment for syphilis. Symptoms include acute fever, headache, and myalgia, usually in patients with early syphilis. Corticosteroid therapy may be considered to prevent potential serious consequences of Jarisch-Herxheimer reaction in non-pregnant patients with cardiovascular syphilis or neurosyphilis.[3] However, evidence of effectiveness is unclear and it is not routinely recommended in some countries.

Iatrogenic procaine reaction (procaine psychosis, procaine mania, Hoigné syndrome) may occur if intramuscular procaine benzylpenicillin is mistakenly administered intravenously. Patients may develop penicillin allergic responses, including anaphylactic shock.[104]

**Treatment details overview**

Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer

<table>
<thead>
<tr>
<th>Initial</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>adults with suspected early infection or sexual contacts of patients with confirmed infection</td>
<td>( summary )</td>
</tr>
<tr>
<td>1st consideration of empirical antibiotics</td>
<td></td>
</tr>
</tbody>
</table>
### Acute

#### (summary)

<table>
<thead>
<tr>
<th>Adults without neurosyphilis</th>
<th>Adults with neurosyphilis</th>
<th>Congenital syphilis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>without penicillin allergy</strong></td>
<td><strong>without penicillin allergy</strong></td>
<td><strong>1st</strong></td>
</tr>
<tr>
<td></td>
<td><strong>1st</strong></td>
<td><strong>intramuscular benzathine benzylpenicillin</strong></td>
</tr>
<tr>
<td></td>
<td><strong>adjunct</strong></td>
<td><strong>oral doxycycline</strong></td>
</tr>
<tr>
<td></td>
<td><strong>adjunct</strong></td>
<td><strong>prednisolone</strong></td>
</tr>
<tr>
<td><strong>with penicillin allergy:</strong></td>
<td><strong>with penicillin allergy:</strong></td>
<td><strong>1st</strong></td>
</tr>
<tr>
<td>non-pregnant</td>
<td>pregnant</td>
<td><strong>adjunct</strong></td>
</tr>
<tr>
<td></td>
<td><strong>1st</strong></td>
<td><strong>densensitisation</strong></td>
</tr>
<tr>
<td></td>
<td><strong>plus</strong></td>
<td><strong>post-desensitisation intramuscular benzathine benzylpenicillin</strong></td>
</tr>
<tr>
<td><strong>with penicillin allergy:</strong></td>
<td><strong>2nd</strong></td>
<td><strong>intramuscular procaine benzylpenicillin</strong></td>
</tr>
<tr>
<td>pregnant</td>
<td></td>
<td><strong>plus oral probenecid</strong></td>
</tr>
<tr>
<td></td>
<td><strong>adjunct</strong></td>
<td><strong>prednisolone</strong></td>
</tr>
<tr>
<td><strong>with penicillin allergy:</strong></td>
<td><strong>2nd</strong></td>
<td><strong>high-dose oral doxycycline</strong></td>
</tr>
<tr>
<td>pregnant</td>
<td></td>
<td><strong>adjunct</strong></td>
</tr>
<tr>
<td><strong>congenital syphilis</strong></td>
<td><strong>1st</strong></td>
<td><strong>intravenous aqueous benzylpenicillin or intramuscular procaine benzylpenicillin</strong></td>
</tr>
<tr>
<td></td>
<td><strong>2nd</strong></td>
<td><strong>intramuscular benzathine benzylpenicillin</strong></td>
</tr>
</tbody>
</table>
Syphilis infection

Treatment

Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer

<table>
<thead>
<tr>
<th>Initial</th>
</tr>
</thead>
<tbody>
<tr>
<td>adults with suspected early infection or sexual contacts of patients with confirmed infection</td>
</tr>
</tbody>
</table>

1st consideration of empirical antibiotics

Primary options

» benzathine benzylpenicillin: 1.8 g intramuscularly as a single dose

Secondary options

» doxycycline: 100 mg orally twice daily

Empirical therapy may be considered in those with suspected early infection (a rash or ulceration) before results of serology are available. Empirical therapy may be appropriate if there are concerns regarding re-attendance. The benefits of empirical therapy (prompt therapy) and risks (potentially unnecessary treatment) should be discussed with the patient.

Intramuscular benzathine benzylpenicillin as a single dose is given. If the patient is allergic to penicillin and is not pregnant, oral doxycycline may be offered.

Sexual contacts of patients with confirmed syphilis should be screened and offered presumptive treatment if follow-up may be problematic.

Treatment course: 14 days (doxycycline)
Syphilis infection

Treatment

**Acute** adults without neurosyphilis

- **without penicillin allergy** 1st

  **Primary options**

  » **intramuscular benzathine benzylpenicillin**

  » **benzathine benzylpenicillin**: primary/secondary/early latent syphilis (first, second, and third trimesters): 1.8 g intramuscularly as a single dose; primary/secondary/early latent syphilis (alternative dosing for third trimester): 1.8 g intramuscularly as a single dose, repeat in 1 week; late-latent/tertiary gummatous syphilis/cardiovascular syphilis: 1.8 g intramuscularly once weekly for 3 weeks

  » The first-line treatment for primary, secondary, and early latent syphilis (without neurosyphilis) is intramuscular benzathine benzylpenicillin as a single dose. Note that the dose may be split and administered at two discrete injection sites.

  » The first-line treatment of late latent and tertiary (gummatous and cardiovascular) syphilis (without neurosyphilis) is intramuscular benzathine benzylpenicillin given as three doses over 2 weeks (days 0, 7, 14).

  » Patients who have symptomatic gummatous syphilis or cardiovascular syphilis should undergo cerebrospinal fluid examination before treatment is started.

  » Pregnant women should receive penicillin-based treatment according to their stage of syphilis. Some specialists recommend that women presenting in the third trimester with early syphilis should receive two injections of benzathine benzylpenicillin, rather than one.

  » Most clinicians treat HIV-positive and HIV-negative individuals with the same penicillin regimens, according to the stage of syphilis.

  » Antibiotic therapy for cardiovascular syphilis does not reverse cardiovascular disease, which may continue to progress after treatment. Discussion with a cardiologist is advised.

- **adjunct** prednisolone

  Treatment recommended for SOME patients in selected patient group

  **Primary options**

  » **prednisolone**: 40-60 mg orally once daily for 3 days; start 24 hours before penicillin
### Acute

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>with penicillin allergy:</strong></td>
<td><strong>non-pregnant</strong></td>
</tr>
<tr>
<td><strong>1st</strong></td>
<td>oral doxycycline</td>
</tr>
</tbody>
</table>

**Primary options**

- **doxycycline**: 100 mg orally twice daily

- If the patient is allergic to penicillin, the first-line treatment in non-pregnant patients is oral doxycycline.

- Adherence and patient compliance may influence treatment outcome if oral therapy is administered.

- Patients who are allergic to penicillin, with primary or secondary syphilis and HIV co-infection, should receive antibiotic therapy as recommended for penicillin-allergic, HIV-negative patients.

- Antibiotic therapy for cardiovascular syphilis does not reverse cardiovascular disease, which may continue to progress after treatment. Discussion with a cardiologist is advised.

- Treatment course: 14 days for primary/secondary/early latent syphilis; 28 days for late latent/tertiary gummatous syphilis/cardiovascular syphilis.

**adjunct prednisolone**

Treatment recommended for SOME patients in selected patient group

**Primary options**

- **prednisolone**: 40-60 mg orally once daily for 3 days; start 24 hours before doxycycline

- Corticosteroid therapy may be considered to minimise the risk of Jarisch-Herxheimer reaction in patients with cardiovascular syphilis. However, evidence of effectiveness is unclear and it is not routinely recommended in some countries.
### Acute

<table>
<thead>
<tr>
<th>with penicillin allergy: pregnant</th>
<th>1st densensitisation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jarisch-Herxheimer reaction is an acute febrile illness that can occur within the first 24 hours after initiation of antibiotic treatment for syphilis. Symptoms include acute fever, headache, and myalgia, usually occurring in patients with early syphilis.</td>
</tr>
<tr>
<td></td>
<td>Penicillin desensitisation is recommended for all patients with penicillin hypersensitivity in pregnancy. The evidence for the use of non-penicillin regimens is relatively weak.</td>
</tr>
<tr>
<td></td>
<td>Penicillin allergy skin testing identifies patients at high risk for penicillin reactions. Skin reagents used should include major and minor allergens. Penicillin desensitisation is usually completed in 4 hours, following which the first dose of penicillin is administered.</td>
</tr>
<tr>
<td></td>
<td>Acute desensitisation can be performed in patients who have a positive skin test to one of the penicillin determinants, and should be performed in a hospital setting. Oral or intravenous desensitisation can be performed, and is usually completed in 4 hours, following which the first dose of penicillin is administered.</td>
</tr>
<tr>
<td>plus post-desensitisation intramuscular benzathine benzylpenicillin</td>
<td>Treatment recommended for ALL patients in selected patient group</td>
</tr>
</tbody>
</table>

#### Primary options

- **benzathine benzylpenicillin**: primary/secondary/early latent syphilis (first, second, and third trimesters): 1.8 g intramuscularly as a single dose; primary/secondary/early latent syphilis (alternative dosing for third trimester): 1.8 g intramuscularly as a single dose, repeat in 1 week; late-latent/tertiary gummatous syphilis/cardiovascular syphilis: 1.8 g intramuscularly once weekly for 3 weeks

- Desensitisation is usually completed in 4 hours, following which the first dose of penicillin is administered.

- Some specialists recommend that women in the third trimester with early syphilis should receive two intramuscular injections of benzathine benzylpenicillin rather than one.
## Syphilis Infection
### Treatment

### Acute

<table>
<thead>
<tr>
<th>without penicillin allergy</th>
<th>1st</th>
<th>intravenous aqueous benzylpenicillin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><strong>Primary options</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>benzylpenicillin sodium:</strong> 10.8 to 14.4 g/day intravenously given in divided doses every 4 hours</td>
</tr>
</tbody>
</table>

- Central nervous system involvement can occur at any stage of syphilis and can range from asymptomatic meningeal involvement to dementia and sensory neuropathy. First-line treatment for neurosyphilis is intravenous aqueous benzylpenicillin.
- Pregnant women should receive penicillin-based treatment according to their stage of syphilis.
- Most clinicians treat HIV-positive and HIV-negative patients with the same penicillin regimens, according to the stage of syphilis. Duration of therapy may be prolonged in patients with HIV and neurosyphilis.

- Treatment course: 10-14 days.

<table>
<thead>
<tr>
<th>adjunct</th>
<th>subsequent intramuscular benzathine benzylpenicillin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Primary options</strong></td>
</tr>
<tr>
<td></td>
<td><strong>benzathine benzylpenicillin:</strong> 1.8 g intramuscularly once weekly</td>
</tr>
</tbody>
</table>

- Some specialists administer benzathine benzylpenicillin once weekly for up to 3 weeks after the intravenous aqueous benzylpenicillin regimen for neurosyphilis has been completed.
- This ensures the duration of treatment is comparable with that of late syphilis in the absence of neurosyphilis.

<table>
<thead>
<tr>
<th>adjunct</th>
<th>prednisolone</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Primary options</strong></td>
</tr>
</tbody>
</table>

- Treatment recommended for SOME patients in selected patient group.
Syphilis infection

**TREATMENT**

This PDF of the BMJ Best Practice topic is based on the web version that was last updated: May 29, 2019. BMJ Best Practice topics are regularly updated and the most recent version of the topics can be found on bestpractice.bmj.com. Use of this content is subject to our disclaimer. © BMJ Publishing Group Ltd 2020. All rights reserved.

<table>
<thead>
<tr>
<th>Acute</th>
<th>2nd</th>
<th>adjunct</th>
</tr>
</thead>
<tbody>
<tr>
<td>» prednisolone: 40-60 mg orally once daily for 3 days; start 24 hours before penicillin</td>
<td>intramuscular procaine benzylpenicillin plus oral probenecid</td>
<td>prednisolone</td>
</tr>
<tr>
<td>» Corticosteroid therapy may be considered to minimise the risk of Jarisch-Herxheimer reaction in patients with non-pregnant patients with neurosyphilis.[3] However, evidence of effectiveness is unclear and it is not routinely recommended in some countries.</td>
<td>Primary options</td>
<td></td>
</tr>
<tr>
<td>» Jarisch-Herxheimer reaction is an acute febrile illness that can occur within the first 24 hours after initiation of antibiotic treatment for syphilis. Symptoms include acute fever, headache, and myalgia, usually occurring in patients with early syphilis.</td>
<td>» procaine benzylpenicillin: 2.4 g intramuscularly once daily -and- probenecid: 500 mg orally four times daily</td>
<td>Primary options</td>
</tr>
<tr>
<td>» Second-line treatment for neurosyphilis is intramuscular procaine benzylpenicillin plus oral probenecid.</td>
<td>» Most clinicians treat HIV-positive and HIV-negative patients with the same penicillin regimens according to the stage of syphilis. Duration of therapy may be prolonged in patients with HIV and neurosyphilis.</td>
<td>» Pregnant women should receive penicillin-based treatment according to their stage of syphilis.</td>
</tr>
<tr>
<td>» Treatment course: 10-14 days.</td>
<td>» Treatment course: 10-14 days.</td>
<td>» Treatment course: 10-14 days.</td>
</tr>
<tr>
<td>Treatment recommended for SOME patients in selected patient group</td>
<td>Treatment recommended for SOME patients in selected patient group</td>
<td>Treatment recommended for SOME patients in selected patient group</td>
</tr>
</tbody>
</table>
### Acute

<table>
<thead>
<tr>
<th>with penicillin allergy</th>
<th>1st desensitisation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jarisch-Herxheimer reaction is an acute febrile illness that can occur within the first 24 hours after initiation of antibiotic treatment for syphilis. Symptoms include acute fever, headache, and myalgia, usually occurring in patients with early syphilis.</td>
</tr>
<tr>
<td></td>
<td>Penicillin desensitisation is recommended for all patients with neurosyphilis who have penicillin hypersensitivity. The evidence for the use of non-penicillin regimes is relatively weak.</td>
</tr>
<tr>
<td></td>
<td>Penicillin allergy skin testing identifies patients at high risk for penicillin reactions. Skin reagents used should include major and minor allergens.[101] Those who are skin-test negative can receive penicillin therapy. However, some clinicians perform desensitisation without skin testing, particularly if the skin reagents for both minor and major determinants of penicillin allergy are not available.</td>
</tr>
<tr>
<td></td>
<td>Acute desensitisation can be performed in patients who have a positive skin test to one of the penicillin determinants, and should be performed in a hospital setting. Oral or intravenous desensitisation can be performed, and is usually completed in 4 hours, following which the first dose of penicillin is administered.[102]</td>
</tr>
<tr>
<td>plus post-desensitisation benzylpenicillin</td>
<td>Treatment recommended for ALL patients in selected patient group</td>
</tr>
</tbody>
</table>

**Primary options**

- benzylpenicillin sodium: 10.8 to 14.4 g/day intravenously given in divided doses every 4 hours

**Secondary options**

- procaine benzylpenicillin: 2.4 g intramuscularly once daily
  - and -
  - probenecid: 500 mg orally four times daily

- Desensitisation is usually completed in 4 hours, following which the first dose of penicillin is administered.[102] Duration of therapy may be prolonged in patients with HIV and neurosyphilis.

- Treatment course: 10-14 days.

**adjunct** subsequent post-desensitisation intramuscular benzathine benzylpenicillin
### Acute

Treatment recommended for SOME patients in selected patient group

**Primary options**

- **benzathine benzylpenicillin**: 1.8 g intramuscularly once weekly

- Some specialists administer benzathine benzylpenicillin once weekly for up to 3 weeks after the treatment regimen for neurosyphilis has been completed (only if first-line intravenous therapy was chosen as the initial therapy).

- This ensures the duration of treatment is comparable with that of late syphilis in the absence of neurosyphilis.

**adjunct** prednisolone

Treatment recommended for SOME patients in selected patient group

**Primary options**

- **prednisolone**: 40-60 mg orally once daily for 3 days; start 24 hours before penicillin

- Corticosteroid therapy may be considered to minimise the risk of Jarisch-Herxheimer reaction in non-pregnant patients with neurosyphilis.[3] However, evidence of effectiveness is unclear and it is not routinely recommended in some countries.

- Jarisch-Herxheimer reaction is an acute febrile illness that can occur within the first 24 hours after initiation of antibiotic treatment for syphilis. Symptoms include acute fever, headache, and myalgia, usually occurring in patients with early syphilis.

**2nd high-dose oral doxycycline**

**Primary options**

- **doxycycline**: 200 mg orally twice daily

- The evidence for the use of non-penicillin regimens is relatively weak. However, high-dose doxycycline is used by some clinicians in this situation.[100]

- Treatment course: 28 days.

**adjunct** prednisolone

Treatment recommended for SOME patients in selected patient group
## Acute

- **prednisolone**: 40-60 mg orally once daily for 3 days; start 24 hours before doxycycline

- Corticosteroid therapy may be considered to minimise the risk of Jarisch-Herxheimer reaction in non-pregnant patients with neurosyphilis. However, evidence of effectiveness is unclear and it is not routinely recommended in some countries.

- Jarisch-Herxheimer reaction is an acute febrile illness that can occur within the first 24 hours after initiation of antibiotic treatment for syphilis. Symptoms include acute fever, headache, and myalgia, usually occurring in patients with early syphilis.

### congenital syphilis

<table>
<thead>
<tr>
<th>Stage</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st</td>
<td>intravenous aqueous benzylpenicillin or intramuscular procaine benzylpenicillin</td>
</tr>
</tbody>
</table>

**Primary options**

- **benzylpenicillin sodium**: consult specialist for guidance on neonatal doses

- OR

  - **procaine benzylpenicillin**: consult specialist for guidance on neonatal doses

- All infants born to mothers with reactive non-treponemal and treponemal tests should have non-treponemal serology (Venereal Disease Research Laboratory or rapid plasma reagin tests) performed on infant serum. False-positive results may occur if umbilical cord blood is sampled, due to contamination of umbilical cord blood with maternal blood.

- First-line treatment of congenital syphilis is intravenous aqueous benzylpenicillin or intramuscular procaine benzylpenicillin. Discussion with an obstetric specialist and neonatologist is recommended. Subsequently, close clinical and serological follow-up by a paediatric specialist is recommended.

- **Treatment course**: 10 days.

- Postnatally-acquired syphilis raises the suspicion of child sexual abuse, which should be investigated further.

| 2nd   | intramuscular benzathine benzylpenicillin |

**Primary options**
Syphilis Infection

**Treatment**

<table>
<thead>
<tr>
<th>Acute</th>
</tr>
</thead>
<tbody>
<tr>
<td>» benzathine benzylpenicillin: consult specialist for guidance on neonatal doses</td>
</tr>
<tr>
<td>» Recommended if a non-treponemal test in the infant is non-reactive and there is low likelihood of infectivity.[5] [103]</td>
</tr>
<tr>
<td>» Covers possible incubating syphilis with close serological follow-up.</td>
</tr>
<tr>
<td>» Discussion with an obstetric specialist recommended.</td>
</tr>
<tr>
<td>» Intramuscular benzathine benzylpenicillin is infrequently used in resource-rich countries. Close clinical and serological follow-up by a paediatric specialist is recommended.</td>
</tr>
<tr>
<td>» Postnatally-acquired syphilis raises the suspicion of child sexual abuse, which should be investigated further.[35]</td>
</tr>
</tbody>
</table>
Emerging

Azithromycin

Azithromycin may be an option in special circumstances only when local susceptibility to azithromycin is likely.[4] Data regarding resistance to azithromycin for treating syphilis in specific settings are not available, and will likely remain unknown. The World Health Organization Guideline Development Group notes concerns about the risk of azithromycin resistance in *Treponema pallidum*. [4]

Ceftriaxone

Ceftriaxone has been used to treat late latent syphilis and neurosyphilis. However, there is no clear consensus regarding the optimal duration of treatment. Results from meta-analyses have found ceftriaxone to be non-inferior to penicillin in terms of cure rates, relapse rates, and serofast rates.[106] [107] In patients with penicillin allergy, there is a low risk of allergic reaction with ceftriaxone due to cross-sensitivity, and it may be given in patients with no history of anaphylaxis.
Recommendations

Monitoring

Non-treponemal tests are repeated to monitor active infection and treatment response. Titres should decline fourfold within 6 months after treatment of primary or secondary syphilis and within 12-24 months after treatment of latent or late syphilis.

Venereal Disease Research Laboratory or rapid plasma reagin titres should be measured monthly after treatment for 3 months, and then every 3 months thereafter. The same non-treponemal test should be used sequentially when monitoring treatment response. This is because results obtained from one test are not directly comparable with that of the other, non-treponemal test.

With effective treatment, non-treponemal tests should become negative. However, some patients who have received adequate treatment become serofast, maintaining a low-level positive titre. This is their baseline titre from which re-infection is assessed.

Following treatment for neurosyphilis, cerebrospinal fluid (CSF) examination should be repeated every 6 months until the white blood cell (WBC) count is normal (if elevated on the initial sample). Re-treatment is considered if the WBC count has not decreased after 6 months or if the CSF remains abnormal after 2 years.[5]

Patient instructions

Patients should be informed that future treponemal-specific testing will reveal previously treated syphilis infection.

Before receiving antibiotic treatment, all patients should be advised of the possibility of the Jarisch-Herxheimer reaction occurring, particularly those patients with early syphilis. The reaction may occur within the first 24 hours after antibiotic therapy due to the rapid killing of treponemes. It is characterised by acute fever, headache, and myalgia. In pregnant women this may cause fetal distress and premature labour.

Patients with primary syphilis should be advised to avoid sexual activities (including oral sex) until the lesions have resolved. Specifically, abstinence from sexual activity is recommended for at least 2 weeks after the lesions of primary syphilis have fully healed, and until 2 weeks after therapy is complete.[3]

Social stigma remains regarding syphilis infection and there may be patient concern about future disclosure issues (e.g., antenatal screening).

Contact tracing of sexual partners should be undertaken to identify asymptomatic patients at risk of syphilis. [CDC: syphilis - fact sheet]

Patient information from recommended websites may be useful. [NHS Choices: syphilis]
### Complications

<table>
<thead>
<tr>
<th>Complications</th>
<th>Timeframe</th>
<th>Likelihood</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jarisch-Herxheimer reaction</td>
<td>short term</td>
<td>high</td>
</tr>
<tr>
<td><strong>Occurs within the first 24 hours after antibiotic therapy due to the rapid killing of treponemes.</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Characterised by acute fever, headache, and myalgia, usually in patients with early syphilis.</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>The likelihood of reaction is high in early syphilis but low in late syphilis. However, all patients should be advised of a possible reaction prior to receiving antibiotic treatment.</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In pregnant women, Jarisch-Herxheimer reaction may cause fetal distress and premature labour.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment is supportive with oral fluids, paracetamol (acetaminophen), and non-steroidal anti-inflammatory drugs.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corticosteroid therapy may be considered to minimise the risk of a Jarisch-Herxheimer reaction in non-pregnant patients with cardiovascular syphilis or neurosyphilis.[3] However, the evidence of effectiveness is unclear and it is not routinely recommended in some countries.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>allergic reaction to penicillin</td>
<td>short term</td>
<td>medium</td>
</tr>
<tr>
<td><strong>May arise in patients not previously known to be allergic.</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In patients with penicillin allergy, alternative treatment options may be offered, dependent on the stage of syphilis.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Penicillin allergy skin testing and desensitisation may be required (e.g., in the treatment of pregnant women).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Penicillin-allergic responses may include urticaria, angio-oedema, and anaphylaxis.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment of allergic reaction is determined by the severity of the reaction.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>iatrogenic procaine reaction</td>
<td>short term</td>
<td>low</td>
</tr>
<tr>
<td><strong>Occurs when intramuscular procaine benzylpenicillin (e.g., used to treat neurosyphilis) is mistakenly administered intravenously.</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients may develop penicillin allergic responses, including anaphylactic shock.[104]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV infection</td>
<td>long term</td>
<td>medium</td>
</tr>
<tr>
<td><strong>Syphilis facilitates the acquisition of HIV.</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>asymptomatic progression of disease</td>
<td>variable</td>
<td>medium</td>
</tr>
<tr>
<td><strong>Organ-specific complications can occur in untreated infection of unknown duration.</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Complications | Timeframe | Likelihood
--- | --- | ---
Specialist opinion should be sought depending on the nature of the complication (e.g., ophthalmology specialist opinion for ocular infection, cardiovascular specialist opinion for aortic regurgitation).

Prognosis

**Natural course of infection**

Treatment is curative once antibiotic treatment is completed. However, re-infection may occur if there is further exposure to syphilis.

The natural course of organ-specific involvement is determined by the stage of syphilis at diagnosis and whether appropriate treatment has been administered. Follow-up of organ-specific complications requires specialist opinion (e.g., cardiology assessment of aortic regurgitation; neurology assessment of tabes dorsalis).

**Serology test results**

Treponemal-specific tests remain reactive lifelong; therefore, they are unable to differentiate between current (active) and past infections. Nor can they be used to monitor response to treatment.

Patients should be informed that future treponemal-specific testing will reveal previously treated syphilis infection.

Non-treponemal tests show a decline in titres or become non-reactive (negative) with effective treatment and are, therefore, used as a quantitative marker of treatment response. Titres should decline fourfold within 6 months after treatment of primary or secondary syphilis, and within 12-24 months after treatment of latent or late syphilis.[108]
## Diagnostic guidelines

### Europe

**The BASHH CEG 2015 summary guidance on tests for sexually transmitted infections**
- **Published by:** British Association for Sexual Health and HIV (BASHH)
- **Last published:** 2015

**UK national guidelines on the management of syphilis**
- **Published by:** British Association for Sexual Health and HIV
- **Last published:** 2015

**2014 European guideline on the management of syphilis**
- **Published by:** International Union against Sexually Transmitted Infections (IUSTI)
- **Last published:** 2014

**UK national guideline on the management of sexually transmitted infections and related conditions in children and young people**
- **Published by:** British Association for Sexual Health and HIV
- **Last published:** 2010

### International

**WHO guideline on syphilis screening and treatment for pregnant women**
- **Published by:** World Health Organization
- **Last published:** 2017

**WHO guidelines for the treatment of Treponema pallidum (syphilis)**
- **Published by:** World Health Organization
- **Last published:** 2016

**Evaluation of rapid diagnostic tests: syphilis**
- **Published by:** World Health Organization; Training in Tropical Diseases
- **Last published:** 2006
## North America

**Screening for syphilis infection in pregnancy**

*Published by:* US Preventive Services Task Force  
*Last published:* 2018

**Syphilis infection in nonpregnant adults and adolescents: screening**

*Published by:* US Preventive Services Task Force  
*Last published:* 2016

**Canadian guidelines on sexually transmitted infections**

*Published by:* Public Health Agency of Canada  
*Last published:* 2016

**Sexually transmitted diseases treatment guidelines, 2015**

*Published by:* Centers for Disease Control and Prevention  
*Last published:* 2015

**Recommendations for partner services programs for HIV infection, syphilis, gonorrhea, and chlamydial infection**

*Published by:* Centers for Disease Control and Prevention (CDC)  
*Last published:* 2008

## Latin America

**Guidance on syphilis testing in Latin America and the Caribbean: improving uptake, interpretation, and quality of testing in different clinical settings**

*Published by:* Pan American Health Organization  
*Last published:* 2015

## Oceania

**Australian STI management guidelines for use in primary care - syphilis**

*Published by:* Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine  
*Last published:* 2018

**Management of sexual health conditions - syphilis**

*Published by:* New Zealand Sexual Health Society  
*Last published:* 2017
## Treatment guidelines

### Europe

<table>
<thead>
<tr>
<th>Guideline</th>
<th>Published by:</th>
<th>Last published:</th>
</tr>
</thead>
<tbody>
<tr>
<td>BASHH CEG 2015 summary guidance on tests for sexually transmitted infections</td>
<td>British Association for Sexual Health and HIV (BASHH)</td>
<td>2015</td>
</tr>
<tr>
<td>UK national guidelines on the management of syphilis</td>
<td>British Association for Sexual Health and HIV (BASHH)</td>
<td>2015</td>
</tr>
<tr>
<td>Barrier methods for contraception and STI prevention</td>
<td>Faculty of Sexual and Reproductive Healthcare</td>
<td>2015</td>
</tr>
<tr>
<td>2014 European guideline on the management of syphilis</td>
<td>International Union against Sexually Transmitted Infections (IUSTI)</td>
<td>2014</td>
</tr>
<tr>
<td>UK national guideline on the management of sexually transmitted infections and related conditions in children and young people</td>
<td>British Association for Sexual Health and HIV (BASHH)</td>
<td>2010</td>
</tr>
</tbody>
</table>

### International

<table>
<thead>
<tr>
<th>Guideline</th>
<th>Published by:</th>
<th>Last published:</th>
</tr>
</thead>
<tbody>
<tr>
<td>WHO guideline on syphilis screening and treatment for pregnant women</td>
<td>World Health Organization (WHO)</td>
<td>2017</td>
</tr>
</tbody>
</table>

### North America

<table>
<thead>
<tr>
<th>Guideline</th>
<th>Published by:</th>
<th>Last published:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sexually transmitted diseases treatment guidelines, 2015</td>
<td>Centers for Disease Control and Prevention (CDC)</td>
<td>2015</td>
</tr>
<tr>
<td>Recommendations for partner services programs for HIV infection, syphilis, gonorrhea, and chlamydial infection</td>
<td>Centers for Disease Control and Prevention (CDC)</td>
<td>2008</td>
</tr>
</tbody>
</table>
## Online resources

1. **USPSTF**: syphilis infection in pregnant women - screening ([external link](#))
2. **USPSTF**: syphilis infection in nonpregnant adults and adolescents - screening ([external link](#))
3. **CDC**: sexually transmitted disease surveillance, 2017 ([external link](#))
4. **NSC**: the UK NSC recommendation on syphilis screening in pregnancy ([external link](#))
5. **BASHH**: update on management of syphilis in pregnancy ([external link](#))
6. **BASHH**: correction to neurosyphilis treatment ([external link](#))
7. **CDC**: syphilis - fact sheet ([external link](#))
8. **NHS Choices**: syphilis ([external link](#))
Key articles

- British Association for Sexual Health and HIV (BASHH). UK national guidelines on the management of syphilis. December 2015 [internet publication]. Full text


References


<table>
<thead>
<tr>
<th>References</th>
</tr>
</thead>
</table>


54. British Association for Sexual Health and HIV (BASHH). United Kingdom national guideline on the management of sexually transmitted infections and related conditions in children and young people - 2010. 2010 [internet publication]. Full text


60. Pan American Health Organization (PAHO). Guidance on syphilis testing in Latin America and the Caribbean: improving uptake, interpretation, and quality of testing in different clinical settings. 2015. 2015 [internet publication]. Full text


<table>
<thead>
<tr>
<th>References</th>
<th>Syphilis infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>83. The World Health Organization. The use of rapid syphilis tests. 2006 [internet publication].</td>
<td></td>
</tr>
<tr>
<td>88. World Health Organization, Department of Reproductive Health and Research. The global elimination of congenital syphilis: rationale and strategy for action. 2007 [internet publication]. <a href="#">Full text</a></td>
<td></td>
</tr>
</tbody>
</table>


Figure 1: Electron micrograph of Treponema pallidum on cultures of cotton-tail rabbit epithelium cells

CDC/Dr David Cox; used with permission
Figure 2: A primary vulvar syphilitic chancre due to Treponema pallidum bacteria

CDC: PHIL image ID 5340; used with permission
Figure 3: A penile chancre located on the proximal penile shaft: primary syphilitic infection

CDC/ Dr Gavin Hart; Dr NJ Fiumara; used with permission
Figure 4: Gummatous lesions on the dorsal surface of the left hand

CDC/Susan Lindsley; used with permission
Figure 5: Secondary syphilitic papulosquamous rash on the torso and upper body

CDC/Susan Lindsley; used with permission
Figure 6: Secondary syphilitic lesions on the face

CDC: PHIL image ID 3500; used with permission
Figure 7: Secondary syphilis presenting pigmented macules and papules on the skin

CDC/Susan Lindsley; used with permission
Figure 8: Secondary syphilitic lesions of vagina

CDC/J. Pledger; used with permission
Figure 9: This was a case of congenital syphilis resulting in the death of this newborn infant

CDC: PHIL image ID 3510; used with permission
Figure 10: This newborn presented with symptoms of congenital syphilis that included lesions on the soles of both feet

CDC: PHIL image ID 4148; used with permission
Figure 11: Interstitial keratitis

CDC/Susan Lindsley
Figure 12: Clutton's joints

CDC/Richard Deitrick; used with permission
Figure 13: Peg-shaped, notched central incisors (Hutchinson's teeth)

CDC/Robert E. Sumpter; used with permission
Figure 14: Osteoperiostitis of the tibia ('saber shins')

CDC/Robert E. Sumpter; used with permission
Disclaimer

This content is meant for medical professionals situated outside of the United States and Canada. The BMJ Publishing Group Ltd ("BMJ Group") tries to ensure that the information provided is accurate and up-to-date, but we do not warrant that it is nor do our licensors who supply certain content linked to or otherwise accessible from our content. The BMJ Group does not advocate or endorse the use of any drug or therapy contained within nor does it diagnose patients. Medical professionals should use their own professional judgement in using this information and caring for their patients and the information herein should not be considered a substitute for that.

This information is not intended to cover all possible diagnosis methods, treatments, follow up, drugs and any contraindications or side effects. In addition such standards and practices in medicine change as new data become available, and you should consult a variety of sources. We strongly recommend that users independently verify specified diagnosis, treatments and follow up and ensure it is appropriate for your patient within your region. In addition, with respect to prescription medication, you are advised to check the product information sheet accompanying each drug to verify conditions of use and identify any changes in dosage schedule or contraindications, particularly if the agent to be administered is new, infrequently used, or has a narrow therapeutic range. You must always check that drugs referenced are licensed for the specified use and at the specified doses in your region. This information is provided on an "as is" basis and to the fullest extent permitted by law the BMJ Group and its licensors assume no responsibility for any aspect of healthcare administered with the aid of this information or any other use of this information.

View our full Website Terms and Conditions.

Contact us
+ 44 (0) 207 111 1105
support@bmj.com

BMJ
BMA House
Tavistock Square
London
WC1H 9JR
UK
Contributors:

// Authors:

**Juan C. Salazar, MD, MPH, FAAP**
Professor and Chair
Department of Pediatrics, University of Connecticut School of Medicine, Hartford, CT
DISCLOSURES: JCS is the author of references cited in this topic.

**Nicholas Bennett, MA (Cantab), MBBChir, PhD**
Associate Professor of Pediatrics
Adjunct Associate Professor of Pharmacy, Department of Pediatrics, University of Connecticut School of Medicine, Hartford, CT
DISCLOSURES: NB declares that he has no competing interests.

**Adriana R. Cruz, MD**
Research Associate
CIDEIM, Cali, Colombia
DISCLOSURES: AC declares that she has no conflicting interests.

// Acknowledgements:

Dr Juan C. Salazar, Dr Nicholas Bennett, and Dr Adriana Cruz would like to gratefully acknowledge Patrick French and Nooshin Barmania, previous contributors to this topic. PF is an author of a reference cited in this topic. NB declares that she has no competing interests.

// Peer Reviewers:

**Robert A. Larsen, MD**
Associate Professor of Medicine
University of Southern California, Keck School of Medicine, Los Angeles, CA
DISCLOSURES: RAL declares that he has no competing interests.

**William Rodriguez, MD**
Assistant Professor of Medicine
Harvard Medical School, Director of Research, Global Health Delivery Project, Harvard School of Public Health, Boston, MA
DISCLOSURES: WR declares that he has no competing interests.

**Jennifer Handforth, MB ChB, MRCPCH, DTM&H**
Consultant Paediatrician
Croydon University Hospital, Croydon, UK
DISCLOSURES: JH declares that she has no competing interests.